



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

12 July 2022  
EMA/CHMP/511583/2022  
Human Medicines Division

## Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 16-19 May 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

### Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

### Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

### Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



# Table of contents

<b>1.</b>	<b>Introduction</b>	<b>8</b>
1.1.	Welcome and declarations of interest of members, alternates and experts.....	8
1.2.	Adoption of agenda .....	8
1.3.	Adoption of the minutes .....	8
<b>2.</b>	<b>Oral Explanations</b>	<b>9</b>
2.1.	Pre-authorisation procedure oral explanations.....	9
2.1.1.	melphalan flufenamide - Orphan - EMEA/H/C/005681 .....	9
2.1.2.	tezepelumab - EMEA/H/C/005588.....	9
2.2.	Re-examination procedure oral explanations .....	9
2.3.	Post-authorisation procedure oral explanations .....	9
2.4.	Referral procedure oral explanations .....	9
2.4.1.	Daruph and Anafezyn - dasatinib (anhydrous) - EMEA/H/A-29(4)/1516 .....	9
2.4.2.	Synchron Research Services – various – EMEA/H/A-31/1515 .....	10
<b>3.</b>	<b>Initial applications</b>	<b>10</b>
3.1.	Initial applications; Opinions.....	10
3.1.1.	Cevenfacta - eptacog beta (activated) - EMEA/H/C/005655 .....	10
3.1.2.	Ertapenem SUN - ertapenem - EMEA/H/C/005815 .....	11
3.1.3.	Ganirelix Gedeon Richter - ganirelix - EMEA/H/C/005641.....	11
3.1.4.	Hervelous - trastuzumab - EMEA/H/C/005880 .....	12
3.1.5.	Kinpeygo - budesonide - Orphan - EMEA/H/C/005653 .....	12
3.1.6.	Sitagliptin/Metformin Hydrochloride Accord - sitagliptin / metformin hydrochloride - EMEA/H/C/005850.....	12
3.1.7.	Sugammadex Fresenius Kabi - sugammadex - EMEA/H/C/005760 .....	13
3.1.8.	Tuznue - trastuzumab - EMEA/H/C/005066.....	13
3.1.9.	Upstaza - eladocagene exuparvovec - Orphan - ATMP - EMEA/H/C/005352.....	14
3.1.10.	Xenpозyme - olipudase alfa - PRIME - Orphan - EMEA/H/C/004850 .....	14
3.1.11.	Zokinvy - lonafarnib - Orphan - EMEA/H/C/005271 .....	15
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) .....	15
3.2.1.	lutrisiran - Orphan - EMEA/H/C/005852.....	15
3.2.2.	mobocertinib - EMEA/H/C/005621 .....	15
3.2.3.	lutetium (177lu) chloride - EMEA/H/C/005859.....	16
3.2.4.	voclosporin - EMEA/H/C/005256.....	16
3.2.5.	octreotide - Orphan - EMEA/H/C/005826 .....	16
3.2.6.	relatlimab / nivolumab - EMEA/H/C/005481 .....	17
3.2.7.	pemetrexed - EMEA/H/C/005848 .....	17

3.2.8.	melphalan flufenamide - Orphan - EMEA/H/C/005681 .....	17
3.2.9.	mitapivat - Orphan - EMEA/H/C/005540 .....	17
3.2.10.	tezepelumab - EMEA/H/C/005588.....	18
3.2.11.	thalidomide - EMEA/H/C/005715 .....	18
3.2.12.	faricimab - EMEA/H/C/005642.....	18
3.2.13.	bevacizumab - EMEA/H/C/005534 .....	19
<b>3.3.</b>	<b>Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) .....</b>	<b>19</b>
3.3.1.	nirsevimab - PRIME - EMEA/H/C/005304 .....	19
3.3.2.	trastuzumab - EMEA/H/C/005769 .....	19
3.3.3.	paclitaxel - EMEA/H/C/005997 .....	19
3.3.4.	teclistamab - PRIME - Orphan - EMEA/H/C/005865.....	20
<b>3.4.</b>	<b>Update on on-going initial applications for Centralised procedure.....</b>	<b>20</b>
3.4.1.	dimethyl fumarate - EMEA/H/C/005963.....	20
3.4.2.	teriparatide - EMEA/H/C/004932 .....	20
3.4.3.	ranibizumab - EMEA/H/C/005610 .....	21
3.4.4.	ruxolitinib - EMEA/H/C/005843.....	21
3.4.5.	ganaxolone - Orphan - EMEA/H/C/005825 .....	21
<b>3.5.</b>	<b>Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 .....</b>	<b>21</b>
<b>3.6.</b>	<b>Initial applications in the decision-making phase.....</b>	<b>21</b>
<b>3.7.</b>	<b>Withdrawals of initial marketing authorisation application .....</b>	<b>22</b>
3.7.1.	HemAryo - eptacog alfa (activated) - EMEA/H/C/005547 .....	22
3.7.2.	Sitoiganap - autologous glioma tumour cells, inactivated / autologous glioma tumour cell lysates, inactivated / allogeneic glioma tumour cells, inactivated / allogeneic glioma tumour cell lysates, inactivated - Orphan - ATMP - EMEA/H/C/003693.....	22

<b>4.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008</b>	<b>22</b>
-----------	---	-----------

<b>4.1.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion .....</b>	<b>22</b>
4.1.1.	Rinvoq - upadacitinib - EMEA/H/C/004760/X/0012/G .....	22
<b>4.2.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues .....</b>	<b>23</b>
4.2.1.	Calquence - acalabrutinib - EMEA/H/C/005299/X/0009/G .....	23
<b>4.3.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question .....</b>	<b>23</b>
4.3.1.	Adcirca - tadalafil - EMEA/H/C/001021/X/0035/G .....	23
4.3.2.	Byfavo - remimazolam - EMEA/H/C/005246/X/0002 .....	24
4.3.3.	Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/X/0101/G.....	24
<b>4.4.</b>	<b>Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 .....</b>	<b>25</b>

<b>4.5.</b>	<b>Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 .....</b>	<b>25</b>
-------------	---	-----------

## **5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008 25**

<b>5.1.</b>	<b>Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information.....</b>	<b>25</b>
5.1.1.	Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0003 .....	25
5.1.2.	Cosentyx - secukinumab - EMEA/H/C/003729/II/0079 .....	26
5.1.3.	Esbriet - pirfenidone - EMEA/H/C/002154/II/0074 .....	26
5.1.4.	Exparel liposomal - bupivacaine - EMEA/H/C/004586/II/0005 .....	26
5.1.5.	Hemlibra - emicizumab - EMEA/H/C/004406/II/0027 .....	27
5.1.6.	Ilaris - canakinumab - EMEA/H/C/001109/II/0075.....	27
5.1.7.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0111 .....	28
5.1.8.	Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0058/G .....	28
5.1.9.	Nexpovio - selinexor - EMEA/H/C/005127/II/0001/G.....	29
5.1.10.	Nuvaxovid - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0009 .....	29
5.1.11.	Olumiant - baricitinib - EMEA/H/C/004085/II/0029/G.....	29
5.1.12.	Ronapreve - casirivimab / imdevimab - EMEA/H/C/005814/II/0002 .....	30
5.1.13.	Veklury - remdesivir - EMEA/H/C/005622/II/0035/G.....	30
5.1.14.	Xeljanz - tofacitinib - EMEA/H/C/004214/II/0039.....	31
5.1.15.	Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0046 .....	31
<b>5.2.</b>	<b>Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .....</b>	<b>32</b>
5.2.1.	Eylea - aflibercept - EMEA/H/C/002392/II/0077/G.....	32
<b>5.3.</b>	<b>Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .....</b>	<b>32</b>

## **6. Medical devices 32**

<b>6.1.</b>	<b>Ancillary medicinal substances - initial consultation .....</b>	<b>32</b>
<b>6.2.</b>	<b>Ancillary medicinal substances – post-consultation update.....</b>	<b>32</b>
<b>6.3.</b>	<b>Companion diagnostics - initial consultation .....</b>	<b>33</b>
6.3.1.	in vitro diagnostic medical device - EMEA/H/D/006078.....	33
6.3.2.	in vitro diagnostic medical device - EMEA/H/D/006065.....	33
<b>6.4.</b>	<b>Companion diagnostics – follow-up consultation.....</b>	<b>33</b>

## **7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 33**

<b>7.1.</b>	<b>Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)</b>	<b>33</b>
-------------	--	-----------

<b>8.</b>	<b>Pre-submission issues</b>	<b>34</b>
<b>8.1.</b>	<b>Pre-submission issue</b> .....	<b>34</b>
8.1.1.	5-amino-3-[4-[[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2s)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide - Orphan - H0005863 .....	34
<b>8.2.</b>	<b>Priority Medicines (PRIME)</b> .....	<b>34</b>
8.2.1.	List of applications received .....	34
8.2.2.	Recommendation for PRIME eligibility.....	34
<b>9.</b>	<b>Post-authorisation issues</b>	<b>34</b>
<b>9.1.</b>	<b>Post-authorisation issues</b> .....	<b>34</b>
9.1.1.	Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) - EMEA/H/C/002333/II/0112.....	34
9.1.2.	Caprelsa - vandetanib - EMEA/H/C/002315/II/0043.....	35
9.1.3.	Defitelio - defibrotide - Orphan - EMEA/H/C/002393/II/0056 .....	35
9.1.4.	Glubrava - Pioglitazone/metformin hydrochloride – EMEA/H/C/000893.....	36
9.1.5.	Lymphoseek - tilmanocept – EMEA/H/C/002085 .....	36
9.1.6.	Ocaliva - obeticholic acid – Orphan - EMEA/H/C/004093/II/0030.....	36
9.1.7.	Orphacol - cholic acid - EMEA/H/C/001250/II/0044.....	37
9.1.8.	Orphacol - cholic acid - EMEA/H/C/001250/II/0045.....	37
9.1.9.	Rasilez HCT - Aliskiren/Hydrochlorothiazide – EMEA/H/C/000964.....	38
9.1.10.	Spikevax - elasomeran - EMEA/H/C/005791/II/0057.....	38
9.1.11.	Tygacil – tigecycline – EMEA/H/C/000644/II/0121 .....	38
9.1.12.	Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0052 .	39
9.1.13.	Zejula - niraparib – Orphan - EMEA/H/C/004249/II/0033 .....	39
9.1.14.	Zynquista – sotagliflozin – EMEA/H/C/004889 .....	39
<b>10.</b>	<b>Referral procedures</b>	<b>40</b>
<b>10.1.</b>	<b>Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004</b> .....	<b>40</b>
<b>10.2.</b>	<b>Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004</b> .	<b>40</b>
<b>10.3.</b>	<b>Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004</b> .....	<b>40</b>
<b>10.4.</b>	<b>Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC</b> .....	<b>40</b>
10.4.1.	Daruph and Anafezyn - dasatinib (anhydrous) - EMEA/H/A-29(4)/1516.....	40
<b>10.5.</b>	<b>Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC....</b>	<b>41</b>
<b>10.6.</b>	<b>Community Interests - Referral under Article 31 of Directive 2001/83/EC</b> .....	<b>41</b>
10.6.1.	Synchron Research Services – various – EMEA/H/A-31/1515 .....	41
<b>10.7.</b>	<b>Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....</b>	<b>42</b>
<b>10.8.</b>	<b>Procedure under Article 107(2) of Directive 2001/83/EC</b> .....	<b>42</b>

<b>10.9.</b>	<b>Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003 .....</b>	<b>42</b>
<b>10.10.</b>	<b>Procedure under Article 29 of Regulation (EC) 1901/2006.....</b>	<b>42</b>
<b>10.11.</b>	<b>Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008 .....</b>	<b>42</b>
<b>11.</b>	<b>Pharmacovigilance issue</b>	<b>42</b>
<b>11.1.</b>	<b>Early Notification System .....</b>	<b>42</b>
<b>12.</b>	<b>Inspections</b>	<b>43</b>
<b>12.1.</b>	<b>GMP inspections .....</b>	<b>43</b>
<b>12.2.</b>	<b>GCP inspections.....</b>	<b>43</b>
<b>12.3.</b>	<b>Pharmacovigilance inspections.....</b>	<b>43</b>
<b>12.4.</b>	<b>GLP inspections .....</b>	<b>43</b>
<b>13.</b>	<b>Innovation Task Force</b>	<b>43</b>
<b>13.1.</b>	<b>Minutes of Innovation Task Force.....</b>	<b>43</b>
<b>13.2.</b>	<b>Innovation Task Force briefing meetings.....</b>	<b>43</b>
<b>13.3.</b>	<b>Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004 .....</b>	<b>43</b>
<b>13.4.</b>	<b>Nanomedicines activities .....</b>	<b>43</b>
<b>14.</b>	<b>Organisational, regulatory and methodological matters</b>	<b>44</b>
<b>14.1.</b>	<b>Mandate and organisation of the CHMP .....</b>	<b>44</b>
14.1.1.	CHMP membership.....	44
14.1.2.	Vote by proxy .....	44
14.1.3.	Seating plan May 2022 CHMP plenary meeting .....	44
14.1.4.	Strategic Review and Learning Meetings (SRLM).....	44
<b>14.2.</b>	<b>Coordination with EMA Scientific Committees.....</b>	<b>44</b>
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC) .....	44
14.2.2.	Paediatric Committee (PDCO).....	44
<b>14.3.</b>	<b>Coordination with EMA Working Parties/Working Groups/Drafting Groups .....</b>	<b>45</b>
14.3.1.	Biologics Working Party (BWP) .....	45
14.3.2.	Name Review Group (NRG).....	45
14.3.3.	Scientific Advice Working Party (SAWP).....	45
14.3.4.	Rheumatology and Immunology Working Party .....	45
14.3.5.	Chair and Vice-Chair election of Working Parties.....	46
14.3.6.	Patients` and Consumers` Working Party (PCWP) and Healthcare Professionals` Working Party (HCPWP) .....	46
14.3.7.	Oncology European Scientific Expert Group (ESEC) .....	46

<b>14.4.</b>	<b>Cooperation within the EU regulatory network.....</b>	<b>46</b>
14.4.1.	Nitrosamines Multidisciplinary Expert Group (NMEG) on rifampicin.....	46
<b>14.5.</b>	<b>Cooperation with International Regulators.....</b>	<b>46</b>
<b>14.6.</b>	<b>Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee.....</b>	<b>47</b>
<b>14.7.</b>	<b>CHMP work plan .....</b>	<b>47</b>
<b>14.8.</b>	<b>Planning and reporting .....</b>	<b>47</b>
<b>14.9.</b>	<b>Others .....</b>	<b>47</b>
<b>15.</b>	<b>Any other business</b>	<b>47</b>
<b>15.1.</b>	<b>AOB topic.....</b>	<b>47</b>
15.1.1.	Update on COVID-19 .....	47
15.1.2.	COVID-19 vaccine – EMEA/H/C/006058.....	47
15.1.3.	Updated questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products .....	47
<b>List of participants</b>		<b>48</b>
<b>Explanatory notes</b>		<b>56</b>

# 1. Introduction

## 1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) pandemic, and the associated EMA Business Continuity Plan (BCP), the meeting was held in-person with some members connected remotely (hybrid setting).

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions taken at this meeting were made in the presence of a quorum of members. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

## 1.2. Adoption of agenda

CHMP agenda for 16-19 May 2022.

The CHMP adopted the agenda.

## 1.3. Adoption of the minutes

CHMP minutes for 19-22 April 2022.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 10 May 2022.

The CHMP adopted the minutes of the April Plenary meeting as well as the minutes from the May PROM meeting.



## 2. Oral Explanations

### 2.1. Pre-authorisation procedure oral explanations

#### 2.1.1. melphalan flufenamide - Orphan - EMEA/H/C/005681

---

Oncopeptides AB; treatment of multiple myeloma

Scope: Possible oral explanation

**Action:** Possible oral explanation to be held on 17 May 2022 at 14:00

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 16.09.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

#### 2.1.2. tezepelumab - EMEA/H/C/005588

---

add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma

Scope: Possible oral explanation

**Action:** Possible oral explanation to be held on 17 May 2022 at 16:00

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 14.10.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

### 2.2. Re-examination procedure oral explanations

No items

### 2.3. Post-authorisation procedure oral explanations

No items

### 2.4. Referral procedure oral explanations

#### 2.4.1. Daruph and Anafezyn - dasatinib (anhydrous) - EMEA/H/A-29(4)/1516

---

Zentiva k.s.

Rapporteur: Filip Josephson, Co-Rapporteur: Armando Genazzani

Scope: Possible oral explanation

**Action:** Possible oral explanation to be held on 18 May 2022 at 09:00

Decentralised Procedure number: SE/H/2098/01-06/DC; SE/H/2099/01-06/DC, notification by the Swedish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting MSs are of the opinion that a positive benefit risk balance is not established under Article 10(3) of Directive 2001/83/EC, as applied, in the absence of bioequivalence and that additional justification is needed to support extrapolation of efficacy and safety to the reference product. Concerns are also raised on the different warning with the reference medicinal product regarding concomitant administration of PPI and /or H2-antagonist and the risk of medication error.

An oral explanation was held on 18 May 2022. The presentation by the applicant focused on the clinical data in support of the application.

See 10.4

#### 2.4.2. Synchron Research Services – various – EMEA/H/A-31/1515

Various

Referral Rapporteur: Kristina Dunder, Referral Co-Rapporteur: Janet Koenig

Scope: Oral explanation

**Action:** Oral explanations to be held on 17 May 2022 at 09:00 and 18 May 2022 at 15:30

Article 31 procedure triggered by the Federal Agency for Medicines and Health Products (FAMHP) in Belgium, the Danish Medicines Agency (DKMA), the Finnish Medicines Agency (Fimea), the Medicines Evaluation Board (MEB) in the Netherlands and the Medical Products Agency (MPA) in Sweden concerning the contract research organisation (CRO) Synchron Research Services, located in Ahmedabad, Gujarat, India.

An oral explanation was held on 17 May. The presentation by the applicants focused on the clinical data in support of the application. The oral explanation on 18 May was cancelled.

See 10.6

## **3. Initial applications**

### **3.1. Initial applications; Opinions**

#### 3.1.1. Cevenfacta - eptacog beta (activated) - EMEA/H/C/005655

Laboratoire Francais du Fractionnement et des Biotechnologies; treatment and for the prevention of bleeding

Scope: Opinion

**Action:** For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that eptacog beta (activated) is not a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

### 3.1.2. [Ertapenem SUN - ertapenem - EMEA/H/C/005815](#)

---

SUN Pharmaceutical Industries (Europe) B.V.; treatment of bacterial infections and prophylaxis of surgical site infection following elective colorectal surgery

Scope: Opinion

**Action:** For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Invanz

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

### 3.1.3. [Ganirelix Gedeon Richter - ganirelix - EMEA/H/C/005641](#)

---

Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.); Prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).

Scope: Opinion

**Action:** For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Orgalutran

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing

authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

#### 3.1.4. Hervalous - trastuzumab - EMEA/H/C/005880

---

Prestige Biopharma Belgium, treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Opinion

**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC), Duplicate of TUZNUE

The Committee adopted a negative opinion by consensus recommending the refusal of the granting of the marketing authorisation. The CHMP assessment report was adopted.

The question-and-answer document was circulated for information.

#### 3.1.5. Kinpeygo - budesonide - Orphan - EMEA/H/C/005653

---

Calliditas Therapeutics AB; treatment of primary immunoglobulin A (IgA) nephropathy

Scope: Opinion

**Action:** For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 24.03.2022, 27.01.2022. List of Questions adopted on 14.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 17 May 2022.

The summary of opinion was circulated for information.

#### 3.1.6. Sitagliptin/Metformin Hydrochloride Accord - sitagliptin / metformin hydrochloride - EMEA/H/C/005850

---

Accord Healthcare S.L.U.; treatment of type 2 diabetes mellitus

Scope: Opinion

**Action:** For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Janumet

---

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

### 3.1.7. Sugammadex Fresenius Kabi - sugammadex - EMEA/H/C/005760

Fresenius Kabi Deutschland GmbH; Reversal of neuromuscular blockade induced by rocuronium or vecuronium.

Scope: Opinion

**Action:** For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Bridion

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

### 3.1.8. Tuznue - trastuzumab - EMEA/H/C/005066

Prestige Biopharma Belgium, treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Opinion

**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 27.01.2022, 25.03.2021, 10.12.2020. List of Questions adopted on 19.09.2019.

The Committee adopted a negative opinion by consensus recommending the refusal of the granting of the marketing authorisation. The CHMP assessment report was adopted.

The question-and-answer document was circulated for information.

### 3.1.9. [Upstaza - eladocagene exuparvovec - Orphan - ATMP - EMEA/H/C/005352](#)

---

PTC Therapeutics International Limited; treatment of aromatic L-amino aciddecarboxylase (AADC) deficiency

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 05.11.2021, 16.04.2021. List of Questions adopted on 20.05.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

Based on the draft opinion prepared by the CAT, the CHMP adopted a positive opinion recommending the granting of a marketing authorisation under exceptional circumstances by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that eladocagene exuparvovec is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 18 May 2022.

The summary of opinion was circulated for information.

### 3.1.10. [Xenpozyme - olipudase alfa - PRIME - Orphan - EMEA/H/C/004850](#)

---

Genzyme Europe BV; treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B.

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 20.04.2022. List of Questions adopted on 22.02.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that olipudase alfa is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 17 May 2022.

The summary of opinion was circulated for information.

### 3.1.11. Zokinvy - lonafarnib - Orphan - EMEA/H/C/005271

---

EigerBio Europe Limited; treatment of Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.04.2022, 16.12.2021, 16.09.2021, 25.02.2021.

List of Questions adopted on 23.07.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation under exceptional circumstances by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that lonafarnib is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 29 April 2022.

The summary of opinion was circulated for information.

## 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

### 3.2.1. vutrisiran - Orphan - EMEA/H/C/005852

---

Alnylam Netherlands B.V.; treatment of hereditary transthyretin-mediated amyloidosis

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 27.01.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.2. mobocertinib - EMEA/H/C/005621

---

Treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 11.11.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed on the need to consult a SAG and adopted a list of questions to this group.

### 3.2.3. lutetium (177lu) chloride - EMEA/H/C/005859

---

is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride.

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 16.12.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.4. voclosporin - EMEA/H/C/005256

---

is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 11.11.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.5. octreotide - Orphan - EMEA/H/C/005826

---

Amryt Pharmaceuticals DAC; treatment of acromegaly

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 16.12.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.



### 3.2.6. [relatlimab / nivolumab - EMEA/H/C/005481](#)

---

indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents (12 years and older and weighing at least 40 kg).

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 27.01.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.7. [pemetrexed - EMEA/H/C/005848](#)

---

treatment of malignant pleural mesothelioma and non-small cell lung cancer

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 16.12.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.8. [melphalan flufenamide - Orphan - EMEA/H/C/005681](#)

---

Oncopeptides AB; treatment of multiple myeloma

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 16.09.2021.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP agreed that an oral explanation was not needed at this time.

The Committee adopted a 2<sup>nd</sup> list of outstanding issues with a specific timetable.

### 3.2.9. [mitapivat - Orphan - EMEA/H/C/005540](#)

---

Agios Netherlands B.V.; treatment of pyruvate kinase deficiency

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on

11.11.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2<sup>nd</sup> list of outstanding issues with a specific timetable.

### 3.2.10. [tezepelumab - EMEA/H/C/005588](#)

---

add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 14.10.2021.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP agreed that an oral explanation was not needed at this time.

The Committee adopted a 2<sup>nd</sup> list of outstanding issues with a specific timetable.

### 3.2.11. [thalidomide - EMEA/H/C/005715](#)

---

treatment of multiple myeloma

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 16.09.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.12. [faricimab - EMEA/H/C/005642](#)

---

treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME)

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 14.10.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.13. bevacizumab - EMEA/H/C/005534

---

Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer. First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer. First-line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

## 3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

### 3.3.1. nirsevimab - PRIME - EMEA/H/C/005304

---

#### **Accelerated assessment**

Prevention of RSV lower respiratory tract infection.

Immunise infants from birth entering their first Respiratory Syncytial Virus (RSV) season for the prevention of RSV lower respiratory tract disease.

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.2. trastuzumab - EMEA/H/C/005769

---

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.3. paclitaxel - EMEA/H/C/005997

---

treatment of metastatic breast cancer

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.4. [teclistamab - PRIME - Orphan - EMEA/H/C/005865](#)

---

##### **Accelerated assessment**

Janssen-Cilag International N.V.; treatment of relapsed or refractory multiple myeloma

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.4. **Update on on-going initial applications for Centralised procedure**

#### 3.4.1. [dimethyl fumarate - EMEA/H/C/005963](#)

---

treatment of multiple sclerosis

Scope: Letter by the applicant dated 16.05.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

**Action:** For adoption

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 27.01.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

#### 3.4.2. [teriparatide - EMEA/H/C/004932](#)

---

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture

Scope: Letter by the applicant dated 11.05.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in December 2021.

**Action:** For adoption

List of Outstanding Issues adopted on 16.12.2021. List of Questions adopted on 28.01.2021.

The CHMP agreed to the request by the applicant for extension to the clock stop to respond to the list of outstanding issues adopted in December 2021.

### 3.4.3. ranibizumab - EMEA/H/C/005610

---

treatment of neovascular age-related macular degeneration in adults

Scope: Letter by the applicant dated 05.05.2022 requesting extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

**Action:** For adoption

List of Outstanding Issues adopted on 22.04.2022, 24.02.2022. List of Questions adopted on 16.09.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

### 3.4.4. ruxolitinib - EMEA/H/C/005843

---

treatment of non-segmental vitiligo

Scope: Letter by the applicant dated 04.05.2022 requesting an extension to the clock stop to respond to the list of questions adopted in February 2022.

**Action:** For adoption

List of Questions adopted on 24.02.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in February 2022.

### 3.4.5. ganaxolone - Orphan - EMEA/H/C/005825

---

Marinus Pharmaceuticals Emerald Limited; treatment of epileptic seizures associated with cyclin dependent kinase-like 5 deficiency disorder (CDD)

Scope: Letter by the applicant dated 09.05.2022 requesting an extension to the clock stop to respond to the list of questions adopted in January 2022.

**Action:** For adoption

List of Questions adopted on 25.01.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in January 2022.

## 3.5. **Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004**

No items

## 3.6. **Initial applications in the decision-making phase**

No items

## 3.7. Withdrawals of initial marketing authorisation application

### 3.7.1. HemAryo - eptacog alfa (activated) - EMEA/H/C/005547

---

UGA Biopharma; treatment of bleeding episodes and for the prevention of bleeding

Scope: Withdrawal of marketing authorisation application

**Action:** For information

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Questions adopted on 11.11.2021.

CHMP noted the withdrawal of the initial marketing authorisation application.

### 3.7.2. Sitoiganap - autologous glioma tumour cells, inactivated / autologous glioma tumour cell lysates, inactivated / allogeneic glioma tumour cells, inactivated / allogeneic glioma tumour cell lysates, inactivated - Orphan - ATMP - EMEA/H/C/003693

---

Epitopoietic Research Corporation-Belgium (E.R.C.); treatment of glioma

Scope: Withdrawal of marketing authorisation application

**Action:** For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.07.2021. List of Questions adopted on 22.01.2021.

CHMP noted the withdrawal of the initial marketing authorisation application.

## 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

### 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

#### 4.1.1. Rinvoq - upadacitinib - EMEA/H/C/004760/X/0012/G

---

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension application to add a new strength (45 mg) of the prolonged-release tablets, grouped with a type II variation (C.I.6.a) for the existing 15 mg and 30 mg strengths to include the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. As a consequence of the extension of indication, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC and the additional risk minimisation measures in the Annex II are updated. The Package Leaflet is updated accordingly. The RMP (version 6.2) is adopted."

**Action:** For adoption

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 27.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

## **4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues**

### **4.2.1. Calquence - acalabrutinib - EMEA/H/C/005299/X/0009/G**

---

AstraZeneca AB

Rapporteur: Filip Josephson, PRAC Rapporteur: Željana Margan Koletić

Scope: "Extension application to introduce a new pharmaceutical form, film-coated tablet. A.6 - To change the ATC Code of acalabrutinib from L01XE51 to L01EL02."

**Action:** For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues, concerning quality and non-clinical aspects.

The Committee adopted a list of outstanding issues with a specific timetable.

## **4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question**

### **4.3.1. Adcirca - tadalafil - EMEA/H/C/001021/X/0035/G**

---

Eli Lilly Nederland B.V.

Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (2 mg/ml oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use (from 6 months to 17 years) based on study 4 (H6D-MC-LVHV [LVHV]) - A 24-week placebo-controlled efficacy and safety study with an open-label long-term extension phase. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The paediatric indication is applicable to the new and all existing presentations. The Package Leaflet and Labelling are updated accordingly. Furthermore, the PI is brought in line with the latest QRD template and editorial changes have been

implemented. The RMP (version 9.1) is updated in accordance.”

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to clinical and multidisciplinary aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 4.3.2. [Byfavo - remimazolam - EMEA/H/C/005246/X/0002](#)

---

PAION Netherlands B.V.

Rapporteur: Bruno Sepodes, Co-Rapporteur: Selma Arapovic Dzakula, PRAC Rapporteur: Rhea Fitzgerald

Scope: “Extension application to introduce a new pharmaceutical form associated with new strength (50 mg powder for concentrate for solution for injection/infusion). The new presentation is indicated to include the intravenous induction and maintenance of general anaesthesia (GA) in adults for Byfavo 50 mg, based on final results from two pivotal trials: Study ONO-2745-05, a phase IIb/III, single-blind, randomised, parallel-group study assessing safety and efficacy in induction and maintenance of anaesthesia in ASA I/II patients (general surgery), and study CNS-7056-022, a phase III, randomized, propofol controlled, parallel group, confirmatory single-blind efficacy and safety trial during induction and maintenance of anaesthesia in ASA III/IV patients. A new combined version of the SmPC, labelling and Package Leaflet solely for the 50 mg strength and the GA indication is provided accordingly. Version 1.2 of the RMP has also been submitted.

As part of the application, the MAH also requests an extension of the market protection by one additional year.”

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to additional market protection aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 4.3.3. [Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/X/0101/G](#)

---

ViiV Healthcare B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber

Scope: “Extension application to introduce a new pharmaceutical form associated with new strength (5 mg/60 mg/30 mg dispersible tablet). The new presentation is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected children weighing at least 14 kg to less than 25 kg.

This extension application is grouped with a type II variation (C.I.6.a) to include treatment of children weighing at least 25 kg for the already approved film-coated tablets for Triumeq (EU/1/14/940/001-002); as a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance.

The RMP (version 19) is updated in accordance.”



**Action:** For adoption

The Committee discussed the issues identified in this application, relating to quality and clinical aspects as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### **4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008**

No items

#### **4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008**

No items

### **5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008**

#### **5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information**

##### **5.1.1. Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0003**

---

BeiGene Ireland Ltd

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) based on results from study BGB-3111-304; an ongoing, international, Phase 3, open-label, multiple-cohort, randomised study designed to evaluate the efficacy of zanubrutinib versus B+R in patients with previously untreated CLL/SLL, and study BGB-3111-305; an ongoing, international Phase 3, open-label, randomized study of zanubrutinib versus ibrutinib with R/R CLL/SLL. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1 and 5.2 of the SmPC are being updated. The Package Leaflet is updated in accordance. An updated RMP version 1.1 (specific for the proposed indication CLL/SLL) was also submitted. In addition, as part of the application, the MAH requested a 1-year extension of the market protection."

**Action:** For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.2. Cosentyx - secukinumab - EMEA/H/C/003729/II/0079

---

Novartis Europharm Limited

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia

Scope: "C.I.6 (Extension of indication)

Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy for Cosentyx alone or in combination with methotrexate; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.2 of the RMP has been approved. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP)."

**Action:** For adoption

Request for Supplementary Information adopted on 27.01.2022, 14.10.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

### 5.1.3. Esbriet - pirfenidone - EMEA/H/C/002154/II/0074

---

Roche Registration GmbH

Rapporteur: Peter Kiely, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension of indication to include treatment of 'advanced' idiopathic pulmonary fibrosis (IPF) by the deletion of the current qualifier 'mild to moderate', based on the results from study MA29957; this is a 52-week Phase IIb, multicentre, randomised, double-blind, placebo-controlled clinical trial in IPF patients with advanced lung function impairment (DLco < 40% of predicted) and at high risk of grade 3 pulmonary hypertension, and additional analyses performed on the original pivotal trials for pirfenidone in IPF. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. In addition, the MAH took the opportunity to include information in section 4.4 of the SmPC related to the content of sodium per Esbriet capsule and tablet. The Package Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted."

**Action:** For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.4. Exparel liposomal - bupivacaine - EMEA/H/C/004586/II/0005

---

Pacira Ireland Limited

Rapporteur: Elita Poplavska, Co-Rapporteur: Margareta Bego, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension of indication to include children over 6 years old."

**Action:** For adoption

Request for Supplementary Information adopted on 16.12.2021.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.5. Hemlibra - emicizumab - EMEA/H/C/004406/II/0027

---

Roche Registration GmbH

Rapporteur: Alexandre Moreau, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include treatment of adult and paediatric patients with haemophilia A without factor VIII (FVIII) inhibitors who have mild or moderate disease for whom prophylaxis is clinically indicated. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC and section 1 of the package leaflet are updated. In addition, section 4.2 is updated to make it clear that the maintenance dose for Hemlibra applies from week 5 of dosing. The PIL is updated accordingly. Version 4.0 of the RMP has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 27.01.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects and the RMP.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

The CHMP agreed on the need to consult an ad-hoc expert group (AHEG) and adopted a list of questions to this group.

#### 5.1.6. Ilaris - canakinumab - EMEA/H/C/001109/II/0075

---

Novartis Europharm Limited

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adult patients with Schnitzler syndrome for Ilaris; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13.0 of the RMP has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 11.11.2021.

The Committee discussed the issues identified in this application, concerning clinical

aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.7. [Keytruda - pembrolizumab - EMEA/H/C/003820/II/0111](#)

---

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, Stage IIC or Stage III melanoma and to include the treatment of adolescents aged 12 years and older with advanced melanoma for Keytruda; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 37 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce editorial improvements in the wording of the indication for MSI-H or dMMR cancers in section 4.1 of the SmPC and update the list of local representatives in the Package Leaflet."

**Action:** For adoption

Request for Supplementary Information adopted on 24.02.2022, 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

#### 5.1.8. [Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0058/G](#)

---

Teva B.V.

Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension of indication to include treatment of the paediatric population for Lonquex and introduction of an age-appropriate presentation in vials; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.1."

**Action:** For adoption

Request for Supplementary Information adopted on 14.10.2021, 12.11.2020.

The Committee discussed the issues identified in this application, concerning quality and clinical aspects.

The Committee adopted a 3<sup>rd</sup> request for supplementary information with a specific timetable.

#### 5.1.9. Nexpovio - selinexor - EMEA/H/C/005127/II/0001/G

---

Karyopharm Europe GmbH

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst

Scope: "Group of variations including an extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and a quality variation for the addition of a new pack size to align with the dose modification guidance for the new indication. Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 6.5 of the SmPC are updated to reflect the new indication and the new pack size. Annex II is updated to reflect the completion of the Specific Obligation. The Labelling and Package Leaflet are amended accordingly. The RMP (v 1.1) is amended consequently."

**Action:** For adoption

Request for Supplementary Information adopted on 24.03.2022, 16.12.2021, 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

#### 5.1.10. Nuvaxovid - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from *Spodoptera frugiperda* - EMEA/H/C/005808/II/0009

---

Novavax CZ, a.s.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include use in adolescents 12 to 17 years of age for Nuvaxovid, based on data from study 2019nCoV-301, a Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to evaluate the efficacy, safety, and immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M Adjuvant in Adult Participants  $\geq$  18 Years with a Paediatric Expansion in Adolescents (12 to < 18 Years); as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted."

**Action:** For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.11. Olumiant - baricitinib - EMEA/H/C/004085/II/0029/G

---

Eli Lilly Nederland B.V.

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski

Scope: "Grouping of the following variations:

C.I.6 - Extension of indication to include treatment of severe alopecia areata in adult patients for Olumiant; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Changes were also made to the PI to bring it in line with the current Agency/QRD template. Version 12.3 of the RMP has been adopted.

C.I.11.z - Update of RMP (version 12.1) to change the category 3 study PASS I4V-MC-B011 end of data collection for the Atopic Dermatitis cohort and the subsequent final study report milestone." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

Request for Supplementary Information adopted on 22.04.2022, 16.12.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

#### 5.1.12. Ronapreve - casirivimab / imdevimab - EMEA/H/C/005814/II/0002

Roche Registration GmbH

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include treatment of COVID-19 in hospitalised patients in adults and adolescents aged 12 years and older weighing at least 40 kg for Ronapreve; as a consequence, sections 4.2, 4.4, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 1.1 of the RMP has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.13. Veklury - remdesivir - EMEA/H/C/005622/II/0035/G

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová

Scope: "Grouped application of two extensions of indication to include:

- treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment, based on interim results from study GS-US-540-5823; a phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics and efficacy of remdesivir in participants from birth to <18 years of age

with COVID-19;

- treatment of paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19, based on data from 8 adolescent patients who were included in study GS-US-540-9012, which was initially assessed by the CHMP as part of procedure II/16 (extension of indication to include treatment of adults).

As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet as well as the instructions for healthcare professionals have been updated accordingly. Version 3.2 of the RMP has also been submitted."

**Action:** For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.14. Xeljanz - tofacitinib - EMEA/H/C/004214/II/0039

Pfizer Europe MA EEIG

Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension of indication to include treatment of active ankylosing spondylitis for Xeljanz prolonged release; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. In addition, editorial changes have been introduced throughout the PI. The Package Leaflet is updated in accordance. Version 28.1 of the RMP has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 16.12.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

#### 5.1.15. Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0046

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Claire Beuneu, CHMP Coordinators: Jan Mueller-Berghaus and Karin Janssen van Doorn, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) for Yescarta; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.3 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the product information with minor editorial changes." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

Request for Supplementary Information adopted on 18.02.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

## **5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

### **5.2.1. Eylea - aflibercept - EMEA/H/C/002392/II/0077/G**

---

Bayer AG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault

Scope: Letter by the applicant dated 09.05.2022 requesting an extension to the clock stop to respond to the request for supplementary information adopted in February 2022.

**Action:** For adoption

Request for supplementary information adopted on 24.02.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the to the request for supplementary information adopted in February 2022.

## **5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

No items

## **6. Medical devices**

### **6.1. Ancillary medicinal substances - initial consultation**

No items

### **6.2. Ancillary medicinal substances – post-consultation update**

No items



### 6.3. Companion diagnostics - initial consultation

#### 6.3.1. in vitro diagnostic medical device - EMEA/H/D/006078

detection of PD-L1 protein

Corresponding medicinal product(s): Keytruda – Pembrolizumab – EMEA/H/C/003820;  
Libtayo – Cemiplimab - EMEA/H/C/004844

Scope: Request for Supplementary Information

**Action:** For adoption

Request for Supplementary Information adopted on 22.04.2022.

The Committee discussed the issues identified in this application, concerning clinical and quality aspects.

The Committee adopted a 2<sup>nd</sup> Request for Supplementary Information with a specific timetable.

#### 6.3.2. in vitro diagnostic medical device - EMEA/H/D/006065

In vitro quantitative determination of anti-Müllerian hormone (AMH) in human serum and plasma

Corresponding medicinal product(s): Rekovelle – Follitropin Delta - EMEA/H/C/003994

Scope: Opinion

**Action:** For adoption

Request for Supplementary Information adopted on 24.03.2022, 22.04.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

### 6.4. Companion diagnostics – follow-up consultation

No items

## 7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

### 7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

## 8. Pre-submission issues

### 8.1. Pre-submission issue

#### 8.1.1. 5-amino-3-[4-[[5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2s)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide - Orphan - H0005863

---

Eli Lilly Nederland B.V., For the treatment of mantle cell lymphoma in adults. For the treatment of chronic lymphocytic leukaemia in adults.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

### 8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

#### 8.2.1. List of applications received

---

**Action:** For information

The CHMP noted the list of applications received.

#### 8.2.2. Recommendation for PRIME eligibility

---

**Action:** For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 3 recommendations for eligibility to PRIME: 1 was denied and 2 were accepted.

The individual outcomes are listed in PRIME Monthly Report on EMA website.

## 9. Post-authorisation issues

### 9.1. Post-authorisation issues

#### 9.1.1. Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) - EMEA/H/C/002333/II/0112

---

GSK Vaccines S.r.l

Rapporteur: Filip Josephson

---

Scope: "Update of section 5.1 of the SmPC in order to add information based on Real World Evidence (RWE) on vaccination impact and effectiveness from literature references available up to July 2021. The MAH also proposes to remove the existing statement related to paediatric studies in section 5.1 of the SmPC. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC."

**Action:** For discussion

The Committee discussed the status of this application.

### 9.1.2. [Caprelsa - vandetanib - EMEA/H/C/002315/II/0043](#)

---

Genzyme Europe BV

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "C.I.4 Update of section 5.1 of the SmPC in order to update pharmacodynamic information based on interim results from study D4200C00104, listed as a specific obligation in the Annex II. This is an observational study (including a retrospective arm to evaluate the Benefit/Risk of vandetanib (Caprelsa) 300 mg in RET mutation negative and RET mutation positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic thyroid cancer (MTC)), to confirm the efficacy and safety of Caprelsa in RET-negative patients with the aim to fulfil SOB001 and convert Caprelsa from conditional to normal Marketing Authorisation. In addition, the MAH takes to opportunity to rectify the Dutch translation of the Caprelsa Product Information."

**Action:** For adoption

Request for Supplementary Information adopted on 16.12.2021, 24.06.2021, 28.05.2020.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 4<sup>th</sup> request for supplementary information with a specific timetable.

### 9.1.3. [Defitelio - defibrotide - Orphan - EMEA/H/C/002393/II/0056](#)

---

Gentium S.r.l.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Submission of the final report from study 15-007 listed as a specific obligation in the Annex II of the Product Information. This is a phase 3, randomised, adaptive study (15-007) of Defibrotide vs. best supportive care in the prevention of hepatic veno-occlusive disease in adult and paediatric patients undergoing hematopoietic stem cell transplant (HSCT). The RMP version 9 has also been submitted.

The MAH has also taken the opportunity to align the PI to the latest QRD template 10.2 which replaces the United Kingdom with United Kingdom (Northern Ireland) in the PIL. In addition, the MAH is correcting the following errata during the linguistic review of the PI: correction of the paragraph number for Regulation (EC) No 726.2004 which was cited incorrectly in Annex II of the French PI and formatting updates to Norwegian and Swedish language PIs."

**Action:** For adoption

Request for Supplementary Information adopted on 10.03.2022, 28.10.2021, 08.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP adopted the DHPC and communication plan.

#### 9.1.4. Glubrava - Pioglitazone/metformin hydrochloride – EMEA/H/C/000893

Takeda Pharma A/S; treatment of diabetes mellitus type 2

Rapporteur: Peter Kiely, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Rhea Fitzgerald

Scope: Withdrawal of marketing authorisation

**Action:** For information

CHMP noted the withdrawal of the marketing authorisation.

#### 9.1.5. Lymphoseek - tilmanocept – EMEA/H/C/002085

CSL Behring GmbH

Rapporteur: Peter Kiley, Co-Rapporteur: Romaldas Mačiulaitis

Scope: DHPC and communication, temporary extension of shelf-life due to shortage of the medicinal product.

**Action:** For adoption

The CHMP adopted the DHPC and communication plan.

#### 9.1.6. Ocaliva - obeticholic acid – Orphan - EMEA/H/C/004093/II/0030

Intercept Pharma International Limited

Rapporteur: Blanca Garcia-Ochoa

Scope: "Update of section 4.3 of the SmPC in order to include a contraindication in patients with decompensated cirrhosis (e.g., Child-Pugh Class B or C) or a prior decompensation event based on interim analyses from the ongoing studies 747-302 and 747-401 listed as Specific Obligations in Annex II and on post-marketing data. Consequently, dosing instructions for patients with CP-B and CP-C cirrhosis were removed from section 4.2, and the wording in sections 4.2, 4.4 and 5.2 of the SmPC have been updated accordingly. In addition, section 4.4 of the SmPC has been updated to include a new warning on monitoring and management of patients for possible progression of PBC and other hepatic adverse reactions. Furthermore, the adverse events of hepatic failure, blood bilirubin increased, jaundice, and hepatic cirrhosis with the frequency unknown were added to section 4.8 of the SmPC in the system organ class (SOC) Hepatobiliary disorders.

The MAH has also taken the opportunity to remove the outdated term "primary biliary cirrhosis" from section 4.1 and to make editorial changes to sections 4.9, 5.1 and Annex IIE

to improve clarity and correct typographical errors. The Package Leaflet is updated accordingly. Also, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2.”

**Action:** For adoption

Request for Supplementary Information adopted on 24.02.2022, 16.12.2021, 16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP adopted the DHPC and communication plan.

#### 9.1.7. [Orphacol - cholic acid - EMEA/H/C/001250/II/0044](#)

---

Laboratoires CTRS

Rapporteur: Anastasia Mountaki

Scope: “Update of sections 4.3 and 4.5 of the SmPC in order to extend the currently existing contraindication with phenobarbital to include primidone based on scientific literature. The Package Leaflet is updated accordingly. In addition, MAH took the opportunity to submit a combined SmPC for both dosages, 50 mg and 250 mg and to introduce editorial changes and update the contact details of the local representatives in the Package Leaflet.”

**Action:** For adoption

Request for Supplementary Information adopted on 24.03.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

#### 9.1.8. [Orphacol - cholic acid - EMEA/H/C/001250/II/0045](#)

---

Laboratoires CTRS

Rapporteur: Anastasia Mountaki

Scope: “Update of section 4.5 of the SmPC in order to update the existing information regarding concomitant use of cholic acid (the active substance of Orphacol) and ursodeoxycholic acid based on scientific literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

**Action:** For adoption

Request for Supplementary Information adopted on 24.03.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

#### 9.1.9. Rasilez HCT - Aliskiren/Hydrochlorothiazide – EMEA/H/C/000964

Noden Pharma DAC; treatment of essential hypertension

Rapporteur: Armando Genazzani, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Amelia Cupelli

Scope: Withdrawal of marketing authorisation

**Action:** For information

CHMP noted the withdrawal of the marketing authorisation.

#### 9.1.10. Spikevax - elasomeran - EMEA/H/C/005791/II/0057

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus

Scope: "Update of section 4.2 of the Spikevax SmPC to include a 50 µg booster dose for adolescents 12 to 18 years of age, based on the extrapolation of safety and efficacy data from young adults (18 to 24 years of age). The package leaflet is updated accordingly."

**Action:** For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

Post meeting note: A revised timetable was adopted via written procedure on 03 June 2022.

#### 9.1.11. Tygacil – tigecycline – EMEA/H/C/000644/II/0121

Pfizer Europe MA EEIG

Rapporteur: Blanca Garcia-Ochoa

Scope: Update of section 5.1 of the SmPC in order to reflect updated breakpoint tables regarding antimicrobial susceptibility testing (EUCAST).

In addition, the MAH is taking the opportunity to update section 4.6 of the SmPC to remove reference to "pharmacodynamic/toxicological" data and update the contact details of the local representatives in the Package Leaflet.

**Action:** For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 9.1.12. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0052

---

AstraZeneca AB

Rapporteur: Sol Ruiz

Scope: "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to introduce a booster dose of Vaxzevria (homologous or heterologous) based on interim immunogenicity and safety data from the pivotal study D7220C00001, a partially double-blinded, randomised, multinational, active-controlled phase II/III clinical study and supportive literature evidence from studies COV001, COV-BOOST and Com-COV studies. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes/corrections throughout the product information."

**Action:** For adoption

Request for Supplementary Information adopted on 22.04.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

#### 9.1.13. Zejula - niraparib – Orphan - EMEA/H/C/004249/II/0033

---

GlaxoSmithKline (Ireland) Limited

Rapporteur: Ingrid Wang, PRAC Rapporteur: Jan Neuhauser

Scope: "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning and add MDS/AML to the list of adverse drug reactions (ADRs) with frequency common, and update of section 5.1 based on final results from the NOVA study (213356); this is a Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer. In addition, the MAH took this opportunity to update sections 4.4 and 4.6 to update information on contraception based on EMA and CTFG recommendations. The Package Leaflet is updated accordingly. The RMP version 6 has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 10.02.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 9.1.14. Zynquista – sotagliflozin – EMEA/H/C/004889

---

Guidehouse Germany GmbH; indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus

Rapporteur: Kristina Dunder, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur:

Martin Huber

Scope: Withdrawal of marketing authorisation

**Action:** For information

CHMP noted the withdrawal of the marketing authorisation.

## 10. Referral procedures

### 10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

### 10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

### 10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

### 10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

#### 10.4.1. Daruph and Anafezyn - dasatinib (anhydrous) - EMEA/H/A-29(4)/1516

---

Zentiva k.s.

Rapporteur: Filip Josephson, Co-Rapporteur: Armando Genazzani

Scope: Opinion

**Action:** For adoption

Decentralised Procedure number: SE/H/2098/01–06/DC; SE/H/2099/01–06/DC, notification by the Swedish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting MSs are of the opinion that a positive benefit risk balance is not established under Article 10(3) of Directive 2001/83/EC, as applied, in the absence of bioequivalence and that additional justification is needed to support extrapolation of efficacy and safety to the reference product. Concerns are also raised on the different warning with the reference medicinal product regarding concomitant administration of PPI and /or H2-antagonist and the risk of medication error.

See 2.4

An oral explanation was held on 18 May 2022. The presentation by the applicant focused on



the clinical data in support of the application.

The CHMP adopted an opinion by majority (28 out of 30 votes) concluding that the marketing authorisation(s) should be granted. The CHMP adopted the assessment report.

The divergent position (Frantisek Drafi and Martina Weise) was appended to the opinion.

The CHMP noted the EMA communication.

## **10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC**

No items

## **10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC**

### **10.6.1. Synchron Research Services – various – EMEA/H/A-31/1515**

---

Various

Referral Rapporteur: Kristina Dunder, Referral Co-Rapporteur: Janet Koenig

Scope: Oral Explanation/Opinion

**Action:** For adoption

Article 31 procedure triggered by the Federal Agency for Medicines and Health Products (FAMHP) in Belgium, the Danish Medicines Agency (DKMA), the Finnish Medicines Agency (Fimea), the Medicines Evaluation Board (MEB) in the Netherlands and the Medical Products Agency (MPA) in Sweden concerning the contract research organisation (CRO) Synchron Research Services, located in Ahmedabad, Gujarat, India.

See 2.4

An oral explanation was held on 17 May 2022. The presentation by the applicants focused on the clinical data in support of the application. The oral explanation on 18 May 2022 was cancelled.

The CHMP adopted an opinion by consensus recommending the suspension of the marketing authorisations of medicinal products which bioequivalence data or justification were not submitted or considered insufficient by the CHMP to establish bioequivalence vis-à-vis the EU reference medicinal product/medicinal product referred in the scientific literature. In Member States where the medicinal product is considered critical, the suspension can be deferred for up to 24 months. The suspensions can be lifted once alternative data establishing bioequivalence are provided.

The CHMP also recommended that medicines that were being evaluated for authorisation for which bioequivalence data or justification were not submitted or considered insufficient to establish bioequivalence vis-à-vis the EU reference medicinal product do not currently satisfy the criteria for authorisation.

For some medicinal products the CHMP concluded that there was alternative data to establish bioequivalence vis-à-vis the EU reference medicinal product, or to demonstrate that the active substance of the medicinal product has been in well-established medicinal

use and recommended the maintenance of these marketing authorisations.

Bioequivalence vis-à-vis the EU reference medicinal product has been established for Tiansan and may continue to be assessed by the relevant national competent authorities for Arrox plus and rosuvastatina/ezetimiba Alter.

The CHMP noted the EMA communication.

#### **10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC**

No items

#### **10.8. Procedure under Article 107(2) of Directive 2001/83/EC**

No items

#### **10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003**

No items

#### **10.10. Procedure under Article 29 of Regulation (EC) 1901/2006**

No items

#### **10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008**

No items

## **11. Pharmacovigilance issue**

### **11.1. Early Notification System**

May 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

**Action:** For information

The CHMP noted the information.

## **12. Inspections**

### **12.1. GMP inspections**

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

### **12.2. GCP inspections**

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

### **12.3. Pharmacovigilance inspections**

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

### **12.4. GLP inspections**

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

## **13. Innovation Task Force**

### **13.1. Minutes of Innovation Task Force**

No items

### **13.2. Innovation Task Force briefing meetings**

No items

### **13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004**

No items

### **13.4. Nanomedicines activities**

No items

## 14. Organisational, regulatory and methodological matters

### 14.1. Mandate and organisation of the CHMP

#### 14.1.1. CHMP membership

---

None

#### 14.1.2. Vote by proxy

---

None

#### 14.1.3. Seating plan May 2022 CHMP plenary meeting

---

**Action:** For information

The CHMP noted the information.

#### 14.1.4. Strategic Review and Learning Meetings (SRLM)

---

CHMP SRLM under the French presidency of the European Union (EU) Council – Paris, 23-24 May 2022

CHMP: Alexandre Moreau

**Action:** For information

The CHMP noted the information.

### 14.2. Coordination with EMA Scientific Committees

#### 14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

---

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for May 2022

**Action:** For adoption

The CHMP adopted the EURD list.

#### 14.2.2. Paediatric Committee (PDCO)

---

PIPs reaching D30 at May 2022 PDCO

**Action:** For information

The CHMP noted the information.

## 14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

### 14.3.1. Biologics Working Party (BWP)

---

Chair: Sol Ruiz

Reports from BWP May 2022 meeting to CHMP for adoption:

- 16 reports on products in scientific advice and protocol assistance
- 15 reports on products in pre-authorisation procedures
- 5 reports on products in post-authorisation procedures
- 5 reports on products in plasma master file

**Action:** For adoption

The CHMP adopted the BWP reports.

### 14.3.2. Name Review Group (NRG)

---

Table of Decisions of the NRG meeting held on 28-29 April 2022.

**Action:** For adoption

The CHMP adopted the table of decisions.

### 14.3.3. Scientific Advice Working Party (SAWP)

---

Chair: Paolo Foggi

Report from the SAWP meeting held on 02-05 May 2022. Table of conclusions

**Action:** For information

The CHMP noted the update.

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

### 14.3.4. Rheumatology and Immunology Working Party

---

Chair: Romaldas Maciulaitis

Appointment of Karolina Torneke as an additional member of the RIWP with expertise in the respiratory field.

**Action:** For endorsement

CHMP appointed Karolina Torneke as an additional member of the RIWP.

#### 14.3.5. Chair and Vice-Chair election of Working Parties

---

Election of chair/vice-chair of the following working parties:

- Infectious Diseases WP
- Cardiovascular Working Party

**Action:** For adoption

The CHMP elected Maria Jesus Fernandez Cortizo as chair, Maja Sommerfelt Grønvold as vice-chair of the Infectious Disease Working Party and Patrick Vrijlandt as vice-chair of the Cardiovascular Working Party.

#### 14.3.6. Patients` and Consumers` Working Party (PCWP) and Healthcare Professionals` Working Party (HCPWP)

---

PCWP: Chair: Juan Garcia Burgos

HCPWP: Chair: Juan Garcia Burgos

- DRAFT Agenda - PCWP-HCPWP Joint meeting - June 2022
- Meeting Summary PCWP-HCPWP meeting 2-3 March 2022
- DRAFT PCWP-HCPWP Work plan 2022-2025

**Action:** For information

The CHMP noted the information.

#### 14.3.7. Oncology European Scientific Expert Group (ESEC)

---

CHMP: Harald Enzmann

Appointment of experts

**Action:** For adoption

CHMP adopted the initial list of experts to the Oncology European Scientific Expert Group (ESEC).

### 14.4. Cooperation within the EU regulatory network

#### 14.4.1. Nitrosamines Multidisciplinary Expert Group (NMEG) on rifampicin

---

NMEG consultation

**Action:** For adoption

CHMP adopted the NMEG consultation on rifampicin.

### 14.5. Cooperation with International Regulators

No items

## 14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

## 14.7. CHMP work plan

No items

## 14.8. Planning and reporting

No items

## 14.9. Others

No items

# 15. Any other business

## 15.1. AOB topic

### 15.1.1. Update on COVID-19

---

**Action:** For information

The CHMP noted the information.

### 15.1.2. COVID-19 vaccine – EMEA/H/C/006058

---

immunisation to prevent COVID-19 caused by SARS-CoV-2

Scope: Rolling review, list of questions

**Action:** For adoption

The CHMP adopted the list of questions on the 1<sup>st</sup> rolling review.

### 15.1.3. Updated questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

---

**Action:** For information

The CHMP noted the information.

## List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 16-19 May 2022 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphly	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No restrictions applicable to this meeting	
Aaron Sosa Mejia	Alternate	Denmark	No restrictions applicable to this meeting	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	



Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Jan Sjöberg	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on	COVID-19 vaccines
Silvijus Abramavicius	Alternate	Lithuania	No restrictions applicable to this meeting	
Martine Trauffer	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Grzegorz Cessak	Alternate	Poland	No participation in final deliberations and voting on	COVID-19 vaccines
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Eva Jirsová	Expert	Czechia	No interests declared	
Michaela Dlouhá	Expert	Czechia	No interests declared	
Petra Vacková	Expert	Czechia	No interests declared	
Ineta Popena	Expert	Latvia	No interests declared	
Janis Kurlovics	Expert	Latvia	No interests declared	
Vita Gulevska	Expert	Latvia	No interests declared	
Vincent Gazin	Expert	France	No interests declared	
Mona Kassem-Youssef	Expert	France	No interests declared	
Jana Schweigertova	Expert	Slovakia	No interests declared	
Eva Malikova	Expert	Slovakia	No interests declared	
Jana Klimasová	Expert	Slovakia	No restrictions applicable to this meeting	
Anna Kubandová	Expert	Slovakia	No interests declared	
Alfredo García-Arieta	Expert	Spain	No interests declared	
Agnieszka Przybyszewska	Expert	Ireland	No interests declared	
Benita Cullen	Expert	Ireland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Elina Asikanius	Expert	Finland	No restrictions applicable to this meeting	
Karri Penttila	Expert	Finland	No interests declared	
Kairi Rooma	Expert	Estonia	No interests declared	
Paula Contreras Alarcón	Expert	Spain	No participation in discussion, final deliberations and voting on	Rinvoq - upadacitinib - EMEA/H/C/004760/X/0012/G
Maria Victoria Tudanca Pacios	Expert	Spain	No restrictions applicable to this meeting	
Mas Parra Paloma	Expert	Spain	No restrictions applicable to this meeting	
Lucia Lopez-Anglada Fernandez	Expert	Spain	No interests declared	
Alicia Pérez González	Expert	Spain	No interests declared	
Antonio Gomez-Outes	Expert	Spain	No interests declared	
Ana Téllez Torres	Expert	Spain	No interests declared	
Lourdes Rodriguez Rojas	Expert	Spain	No interests declared	
Cornelis Frank Tuinenburg	Expert	Netherlands	No interests declared	
Nancy Postma	Expert	Netherlands	No interests declared	
Jessica Harskamp	Expert	Netherlands	No interests declared	
Michel Kooijman	Expert	Netherlands	No interests declared	
Chaya Gopie	Expert	Netherlands	No interests declared	
Eleonora Wijnans	Expert	Netherlands	No interests declared	
Ingrid Schellens	Expert	Netherlands	No interests declared	
Katrien Oude Rengerink	Expert	Netherlands	No participation in discussion, final deliberations and voting on	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0111
Marianne Kuijpers	Expert	Netherlands	No interests declared	
Nienke Rodenhuis	Expert	Netherlands	No interests declared	
Hester Peltenburg	Expert	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Jaap Fransen	Expert	Netherlands	No interests declared	
Hilke Zander	Expert	Germany	No interests declared	
Sara Tognarelli	Expert	Germany	No restrictions applicable to this meeting	
Annette Lommel	Expert	Germany	No interests declared	
Bettina Klug	Expert	Germany	No interests declared	
Linda Marchioro	Expert	Germany	No interests declared	
Lukas Malte Aguirre Davila	Expert	Germany	No interests declared	
Attila Sebe	Expert	Germany	No interests declared	
Susanne Mueller-Egert	Expert	Germany	No interests declared	
Jens Peter Hartmann	Expert	Germany	No interests declared	
Paolo Foggi	Expert	Italy	No interests declared	
Adriana Ammassari	Expert	Italy	No interests declared	
Luca Santi	Expert	Italy	No restrictions applicable to this meeting	
Martina Perini	Expert	Italy	No restrictions applicable to this meeting	
Angelo Molinaro	Expert	Italy	No interests declared	
Antonella Isgrò	Expert	Italy	No interests declared	
Odoardo Maria Olimpieri	Expert	Italy	No interests declared	
Gabriella Passacquale	Expert	Italy	No interests declared	
Camilla Festa	Expert	Italy	No interests declared	
Floriana D'Urso	Expert	Italy	No interests declared	
Alessia Proietti	Expert	Italy	No interests declared	
Andrea Logreco	Expert	Italy	No interests declared	
Marco Di Girolamo	Expert	Italy	No interests declared	
Valeria Di Muzio	Expert	Italy	No interests declared	
Cristina Migali	Expert	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Pia Rivetti di Val Cervo	Expert	Italy	No interests declared	
Serena Zamponi	Expert	Italy	No participation in discussion, final deliberations and voting on	pemetrexed - EMEA/H/C/005848 Glubrava - Pioglitazone/metformin hydrochloride - EMEA/H/C/000893 mobocertinib - EMEA/H/C/005621
Mette Linnert Jensen	Expert	Denmark	No interests declared	
Susanne Høpner Rasmussen	Expert	Denmark	No interests declared	
Deirdre Mannion	Expert	Denmark	No restrictions applicable to this meeting	
Claus Stage	Expert	Denmark	No restrictions applicable to this meeting	
Kristina Bech Jensen	Expert	Denmark	No interests declared	
Kristin Skougaard	Expert	Denmark	No interests declared	
Anne-Marie Dalseg	Expert	Denmark	No interests declared	
Anne-Berit Erdal	Expert	Norway	No participation in final deliberations and voting on	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0111
Hatice Canan Bayar	Expert	Norway	No interests declared	
Fabienne Gaugazova	Expert	Sweden	No interests declared	
Erika Fredriksson	Expert	Sweden	No interests declared	
Hanna Kastman	Expert	Sweden	No interests declared	
Irene Bachmann	Expert	Germany	No interests declared	
Nora Cascante Estepa	Expert	Germany	No interests declared	
Jutta Dedorath	Expert	Germany	No interests declared	
Katalina Mettke	Expert	Germany	No interests declared	
George Aislaitner	Expert	Germany	No interests declared	
Stephanie Buchholz	Expert	Germany	No interests declared	
An Na Joo	Expert	Sweden	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Charlotte Anderberg	Expert	Sweden	No restrictions applicable to this meeting	
Daiana Vasilcanu	Expert	Sweden	No interests declared	
Mikael Andersson	Expert	Sweden	No interests declared	
Larissa Higgins	Expert	Ireland	No interests declared	
Rosalía Ruano Camps	Expert	Spain	No interests declared	
Andre Elferink	Expert	Netherlands	No interests declared	
Elisabeth Wischnitzki	Expert	Austria	No interests declared	
Franz Rieder-Rommer	Expert	Austria	No interests declared	
Walter Johannes Beiersdorf	Expert	Austria	No restrictions applicable to this meeting	
Bojana Divkovic	Expert	Austria	No restrictions applicable to this meeting	
Angelina Doriguzzi	Expert	Austria	No restrictions applicable to this meeting	
Hannah Münch	Expert	Austria	No interests declared	
Valeria Zoccano	Expert	Italy	No interests declared	
Danila Renzo	Expert	Italy	No interests declared	
Martina Schuessler-Lenz	Expert	Germany	No interests declared	
Maria Linnea Asp	Expert	Sweden	No restrictions applicable to this meeting	
Helena Back	Expert	Sweden	No interests declared	
Helena Faust	Expert	Sweden	No interests declared	
Inne Crèvecoeur	Expert	Belgium	No restrictions applicable to this meeting	
Violette Dirix	Expert	Belgium	No interests declared	
Olga Kholmanskikh	Expert	Belgium	No interests declared	
Valerie Lescrainier	Expert	Belgium	No interests declared	
Clemens Mittmann	Expert	Germany	No interests declared	
Claire-Li Ding	Expert	France	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Patrick Vrijlandt	Expert	Netherlands	No interests declared	
Agustin Portela Moreira	Expert	Spain	No interests declared	
Carla Herberts	Expert	Netherlands	No interests declared	
Silvia Perez Lopez	Expert	Spain	No interests declared	
Sara Galluzzo	Expert	Italy	No interests declared	
Elma O'Reilly	Expert	Ireland	No interests declared	
Pierre Demolis	Expert	France	No interests declared	
Sigrid Klaar	Expert	Sweden	No restrictions applicable to this meeting	
Filip Kukulski	Expert	Health Canada	No interests declared	
Evelyn Soo	Expert	Health Canada	No interests declared	
Megan Hickie	Expert	TGA	No interests declared	
Lothar Bergmann	Expert	Germany	No restrictions applicable to this meeting	
A representative from the European Commission attended the meeting.				
Meeting run with support from relevant EMA staff.				

Experts were evaluated against the agenda topics or activities they participated in.

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

## Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

### Oral explanations (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

### Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.



### **Extension of marketing authorisations according to Annex I of Reg. 1234/2008** (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

### **Type II variations - Extension of indication procedures** (section 5)

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

### **Ancillary medicinal substances in medical devices** (section 6)

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

### **Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004** (section 3.5)

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

### **Re-examination procedures** (section 5.3)

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

### **Withdrawal of application** (section 3.7)

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

### **Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use)** (section 7)

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

### **Pre-submission issues** (section 8)

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

### **Post-authorisation issues** (section 9)

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

### **Referral procedures** (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found [here](#).

### **Pharmacovigilance issues** (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

### **Inspections Issues** (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

### **Innovation task force** (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

### **Scientific advice working party (SAWP)** (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

### **Satellite groups / other committees** (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

### **Invented name issues** (section 14.3)

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)



12 July 2022  
EMA/CHMP/286514/2022

## Annex to 16-19 May 2022 CHMP Minutes

### Pre-submission and post-authorisations issues

<b>A. PRE-SUBMISSION ISSUES .....</b>	<b>3</b>
A.1. ELIGIBILITY REQUESTS.....	3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications .....	3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION .....	3
<b>B. POST-AUTHORISATION PROCEDURES OUTCOMES .....</b>	<b>3</b>
B.1. Annual re-assessment outcomes .....	3
B.1.1. Annual reassessment for products authorised under exceptional circumstances .....	3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES.....	3
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal .....	3
B.2.2. Renewals of Marketing Authorisations for unlimited validity.....	3
B.2.3. Renewals of Conditional Marketing Authorisations.....	5
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES.....	6
B.4. EPARs / WPARs .....	8
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES .....	10
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects .....	10
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	15
B.5.3. CHMP-PRAC assessed procedures .....	27
B.5.4. PRAC assessed procedures.....	36
B.5.5. CHMP-CAT assessed procedures .....	40
B.5.6. CHMP-PRAC-CAT assessed procedures .....	41
B.5.7. PRAC assessed ATMP procedures .....	41
B.5.8. Unclassified procedures and worksharing procedures of type I variations.....	41
B.5.9. Information on withdrawn type II variation / WS procedure .....	43
B.5.10. Information on type II variation / WS procedure with revised timetable.....	43
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION .....	43
B.6.1. Start of procedure for New Applications: timetables for information .....	43
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information .....	44



B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information.....	44
B.6.4. Annual Re-assessments: timetables for adoption .....	45
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed .....	46
B.6.6. VARIATIONS – START OF THE PROCEDURE.....	47
B.6.7. Type II Variations scope of the Variations: Extension of indication .....	47
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects .....	52
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	54
B.6.10. CHMP-PRAC assessed procedures.....	61
B.6.11. PRAC assessed procedures .....	64
B.6.12. CHMP-CAT assessed procedures .....	66
B.6.13. CHMP-PRAC-CAT assessed procedures.....	66
B.6.14. PRAC assessed ATMP procedures .....	67
B.6.15. Unclassified procedures and worksharing procedures of type I variations .....	67
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY.....	69
B.7.1. Yearly Line listing for Type I and II variations.....	69
B.7.2. Monthly Line listing for Type I variations.....	69
B.7.3. Opinion on Marketing Authorisation transfer (MMD only) .....	69
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only) .....	69
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only) .....	69
B.7.6. Notifications of Type I Variations (MMD only) .....	69
<b>C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled) .....</b>	<b>69</b>
<b>D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed) .....</b>	<b>69</b>
<b>E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES .....</b>	<b>69</b>
E.1. PMF Certification Dossiers:.....	69
E.1.1. Annual Update.....	69
E.1.2. Variations: .....	69
E.1.3. Initial PMF Certification:.....	69
E.2. Time-Tables – starting & ongoing procedures: For information .....	69
<b>F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver ....</b>	<b>70</b>
<b>G. ANNEX G.....</b>	<b>70</b>
G.1. Final Scientific Advice (Reports and Scientific Advice letters): .....	70
G.2. PRIME.....	70
G.2.1. List of procedures concluding at 16-19 May 2022 CHMP plenary:.....	70
G.2.2. List of procedures starting in May 2022 for June 2022 CHMP adoption of outcomes	70
<b>H. ANNEX H - Product Shared Mailboxes – e-mail address.....</b>	<b>70</b>

## A. PRE-SUBMISSION ISSUES

### A.1. ELIGIBILITY REQUESTS

---

Report on Eligibility to Centralised Procedure for May 2022: **For adoption** Adopted

---

### A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

---

Final Outcome of Rapporteurship allocation for May 2022: **For adoption** Adopted

---

### A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

## B. POST-AUTHORISATION PROCEDURES OUTCOMES

### B.1. Annual re-assessment outcomes

#### B.1.1. Annual reassessment for products authorised under exceptional circumstances

---

<b>Raxone - idebenone - EMEA/H/C/003834/S/0029, Orphan</b> Santhera Pharmaceuticals (Deutschland) GmbH, Rapporteur: John Joseph Borg, PRAC Rapporteur: Amelia Cupelli Request for Supplementary Information adopted on 24.03.2022, 27.01.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.  The Marketing Authorisation remains under exceptional circumstances.
--	---

---

### B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

#### B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

#### B.2.2. Renewals of Marketing Authorisations for unlimited validity

---

<b>Alecensa - alectinib - EMEA/H/C/004164/R/0039</b> Roche Registration GmbH, Rapporteur: Filip Josephson, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Jana Lukacisinova	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.  Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
--	--

---

---

<b>Elebrato Ellipta - fluticasone furoate / umeclidinium / vilanterol -</b>	Positive Opinion adopted by consensus together with the CHMP assessment report and
---	--

---

<p><b>EMEA/H/C/004781/R/0026</b>  GlaxoSmithKline Trading Services Limited,  Duplicate, Duplicate of Trelegy Ellipta,  Rapporteur: Peter Kiely, Co-Rapporteur: Janet  Koenig, PRAC Rapporteur: Annika Folin</p>	<p>translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p><b>Fotivda - tivozanib -</b>  <b>EMEA/H/C/004131/R/0021</b>  EUSA Pharma (Netherlands) B.V., Rapporteur:  Bruno Sepodes, Co-Rapporteur: Romaldas  Mačiulaitis, PRAC Rapporteur: Rugile Pilviniene  Request for Supplementary Information adopted  on 24.03.2022.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p><b>LUTATHERA - lutetium (177Lu) oxodotreotide -</b>  <b>EMEA/H/C/004123/R/0032, Orphan</b>  Advanced Accelerator Applications, Rapporteur:  Janet Koenig, Co-Rapporteur: Thalia Marie  Estrup Blicher, PRAC Rapporteur: Adam  Przybylkowski  Request for Supplementary Information adopted  on 24.03.2022.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p><b>Nyxoïd - naloxone -</b>  <b>EMEA/H/C/004325/R/0014</b>  Mundipharma Corporation (Ireland) Limited,  Rapporteur: Bruno Sepodes, Co-Rapporteur:  Elita Poplavskã, PRAC Rapporteur: Liana Gross-  Martirosyan  Request for Supplementary Information adopted  on 19.05.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Ontruzant - trastuzumab -</b>  <b>EMEA/H/C/004323/R/0040</b>  Samsung Bioepis NL B.V., Rapporteur: Karin  Janssen van Doorn, Co-Rapporteur: Elita  Poplavskã, PRAC Rapporteur: Brigitte Keller-  Stanislowski</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p><b>Ritonavir Mylan - ritonavir -</b>  <b>EMEA/H/C/004549/R/0015</b>  Mylan Pharmaceuticals Limited, Generic,  Generic of Norvir, Rapporteur: John Joseph  Borg, PRAC Rapporteur: Liana Gross-  Martirosyan  Request for Supplementary Information adopted  on 19.05.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Tacforius - tacrolimus -</b></p>	<p>Request for supplementary information adopted</p>

<p><b>EMA/H/C/004435/R/0010</b>  Teva B.V., Generic, Generic of Advagraf,  Rapporteur: Daniela Philadelphly, PRAC  Rapporteur: Ronan Grimes  Request for Supplementary Information adopted  on 19.05.2022.</p>	<p>with a specific timetable.</p>
<p><b>Trelegy Elipta - fluticasone furoate /  umeclidinium / vilanterol -  EMA/H/C/004363/R/0023</b>  GlaxoSmithKline Trading Services Limited,  Rapporteur: Peter Kiely, Co-Rapporteur: Janet  Koenig, PRAC Rapporteur: Annika Folin</p>	<p>Positive Opinion adopted by consensus together  with the CHMP assessment report and  translation timetable.</p> <p>Based on the review of the available  information, the CHMP was of the opinion that  the renewal of the marketing authorisation can  be granted with unlimited validity.</p>
<p><b>Tremfya - guselkumab -  EMA/H/C/004271/R/0033</b>  Janssen-Cilag International N.V., Rapporteur:  Agnes Gyurasics, Co-Rapporteur: Peter Kiely,  PRAC Rapporteur: Brigitte Keller-Stanislawski</p>	<p>Positive Opinion adopted by consensus together  with the CHMP assessment report and  translation timetable.</p> <p>Based on the review of the available  information, the CHMP was of the opinion that  the renewal of the marketing authorisation can  be granted with unlimited validity.</p>
<p><b>VeraSeal - human fibrinogen / human  thrombin - EMA/H/C/004446/R/0018</b>  Instituto Grifols, S.A., Rapporteur: Andrea  Laslop, Co-Rapporteur: Ewa Balkowiec Iskra,  PRAC Rapporteur: Amelia Cupelli  Request for Supplementary Information adopted  on 19.05.2022.</p>	<p>Request for supplementary information adopted  with a specific timetable.</p>
<p><b>Zejula - niraparib -  EMA/H/C/004249/R/0034, Orphan</b>  GlaxoSmithKline (Ireland) Limited, Rapporteur:  Ingrid Wang, Co-Rapporteur: Alexandre Moreau,  PRAC Rapporteur: Jan Neuhauser</p>	<p>Positive Opinion adopted by consensus together  with the CHMP assessment report and  translation timetable.</p> <p>Based on the review of the available  information, the CHMP was of the opinion that  the renewal of the marketing authorisation can  be granted with unlimited validity.</p>
<p><b>Zubsolv - buprenorphine / naloxone -  EMA/H/C/004407/R/0019</b>  Accord Healthcare S.L.U., Rapporteur: Peter  Kiely, Co-Rapporteur: Tomas Radimersky, PRAC  Rapporteur: Martin Huber</p>	<p>Positive Opinion adopted by consensus together  with the CHMP assessment report and  translation timetable.</p> <p>Based on the review of the available  information, the CHMP was of the opinion that  the renewal of the marketing authorisation can  be granted with unlimited validity.</p>
<p><b>B.2.3. Renewals of Conditional Marketing Authorisations</b></p>	
<p><b>AYVAKYT - avapritinib -  EMA/H/C/005208/R/0017, Orphan</b></p>	<p>Positive Opinion adopted by consensus together  with the CHMP assessment report and</p>

---

Blueprint Medicines (Netherlands) B.V.,  
Rapporteur: Blanca Garcia-Ochoa, PRAC  
Rapporteur: Menno van der Elst

translation timetable.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

---

**Idefirix - imlifidase -**  
**EMA/H/C/004849/R/0007, Orphan**  
Hansa Biopharma AB, Rapporteur: Martina Weise, Co-Rapporteur: Kristina Dunder, PRAC  
Rapporteur: Menno van der Elst  
Request for Supplementary Information adopted on 22.04.2022.

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

---

**MINJUVI - tafasitamab -**  
**EMA/H/C/005436/R/0003, Orphan**  
Incyte Biosciences Distribution B.V.,  
Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Alexandre Moreau, PRAC  
Rapporteur: Annika Folin

Positive Opinion adopted by consensus together with the CHMP assessment report.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

---

**VITRAKVI - larotrectinib -**  
**EMA/H/C/004919/R/0024**  
Bayer AG, Rapporteur: Filip Josephson, PRAC  
Rapporteur: Rugile Pilviniene  
Request for Supplementary Information adopted on 19.05.2022.

Request for supplementary information adopted with a specific timetable.

---

### **B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES**

---

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its May 2022 meeting:

---



---

**EMA/H/C/PSUSA/00010029/202110**

(dapagliflozin)

CAPS:

**Edistride** (EMA/H/C/004161) (dapagliflozin),  
AstraZeneca AB, Rapporteur: Kristina Dunder

**Forxiga** (EMA/H/C/002322) (dapagliflozin),  
AstraZeneca AB, Rapporteur: Kristina Dunder,  
PRAC Rapporteur: Annika Folin, "05/10/2020  
To: 04/10/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):  
Update of sections 4.8 of the SmPC to add the adverse reaction tubulointerstitial nephritis with a frequency "very rare", and 4.5 of the SmPC to add an interaction between dapagliflozin and lithium. The package leaflet is updated accordingly.

---

**EMA/H/C/PSUSA/00010733/202109**

(galcanezumab)

CAPS:

**Emgality** (EMA/H/C/004648)

(galcanezumab), Eli Lilly Nederland B.V.,  
Rapporteur: Armando Genazzani, PRAC  
Rapporteur: Kirsti Villikka, "28/03/2021 To:  
27/09/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):  
Update of section 4.4 of the SmPC to add information that serious hypersensitivity reactions may occur more than 1 day to four weeks after administration and be prolonged in duration. The package leaflet is updated accordingly.

---

**EMA/H/C/PSUSA/00010818/202109**

(siponimod)

CAPS:

**Mayzent** (EMA/H/C/004712) (siponimod),  
Novartis Europharm Limited, Rapporteur:  
Thalia Marie Estrup Blicher, PRAC Rapporteur:  
Maria del Pilar Rayon, "26/03/2021 To:  
25/09/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the abovementioned medicinal product(s), concerning the following change(s):  
Update of the sections 4.4 and 4.8 of the SmPC to add squamous cell carcinoma with a frequency uncommon. The Package Leaflet section 4 and the Patient/Caregiver guide (Annex IID) are updated accordingly.  
Update of section 4.4 of the SmPC to include a warning about herpes viral infection and an amendment of subsection "Description of selected adverse reactions" in the section 4.8.  
The Package Leaflet section 2, Physician's checklist and the Patient/Caregiver guide (Annex IID) are updated accordingly.  
Update of section 4.4 of the SmPC to amend the warning about cryptococcal meningitis and section 4.8 to include this ADR in the tabulated list of adverse reactions. The Package Leaflet section 4, Physician's checklist and the Patient/Caregiver guide (Annex IID) are updated accordingly.  
Update of the RMP Parts II, V, VI and Annex 6 to align with the changes in the SmPC. The final approved RMP version number 4.2.

---

**B.4. EPARs / WPARs**

---

**Actrapid - insulin human -****EMA/H/W/005779, Article 58**

Novo Nordisk A/S, treatment of diabetes mellitus, Known active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**Filsuvez - birch bark extract -****EMA/H/C/005035, Orphan**

Amryt Pharmaceuticals DAC, Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older, Known active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**HemAryo (WD) - eptacog alfa (activated) -****EMA/H/C/005547**

For information only. Comments can be sent to the PL in case necessary.

---

---

UGA Biopharma, treatment of bleeding episodes and for the prevention of bleeding, Similar biological application (Article 10(4) of Directive No 2001/83/EC)

**WPAR**

---

**Insulatard - insulin human - EMEA/H/W/005780, Article 58**

Novo Nordisk A/S, treatment of diabetes mellitus, Known active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**LUNSUMIO - mosunetuzumab - EMEA/H/C/005680, Orphan**

Roche Registration GmbH, refractory follicular lymphoma (FL), New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**Pirfenidone AET - pirfenidone - EMEA/H/C/005873**

Alfred E. Tiefenbacher (GmbH & Co. KG), treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), Generic, Generic of Esbriet, Generic application (Article 10(1) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**SITOIGANAP (WD) - autologous glioma tumour cells, inactivated / autologous glioma tumour cell lysates, inactivated / allogeneic glioma tumour cells, inactivated / allogeneic glioma tumour cell lysates, inactivated - EMEA/H/C/003693, Orphan, ATMP**

Epitopoietic Research Corporation-Belgium (E.R.C.), treatment of glioma, New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

**WPAR**

---

**Tabrecta - capmatinib - EMEA/H/C/004845**

Novartis Europharm Limited, treatment of non-small cell lung cancer (NSCLC), New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**Yselty - linzagolix choline - EMEA/H/C/005442**

ObsEva Ireland Ltd, for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids, New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

## B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

### B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

<b>Benepali - etanercept - EMA/H/C/004007/II/0063/G</b> Samsung Bioepis NL B.V., Rapporteur: Andrea Laslop Opinion adopted on 12.05.2022.	Positive Opinion adopted by consensus on 12.05.2022.
<b>Benlysta - belimumab - EMA/H/C/002015/II/0104</b> GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder Opinion adopted on 19.05.2022.	Positive Opinion adopted by consensus on 19.05.2022.
<b>Bimzelx - bimekizumab - EMA/H/C/005316/II/0003/G</b> UCB Pharma S.A., Rapporteur: Peter Kiely Opinion adopted on 19.05.2022. Request for Supplementary Information adopted on 24.03.2022, 13.01.2022.	Positive Opinion adopted by consensus on 19.05.2022.
<b>COMIRNATY - tozinameran - EMA/H/C/005735/II/0125/G</b> BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 12.05.2022.	Positive Opinion adopted by consensus on 12.05.2022.
<b>COMIRNATY - tozinameran - EMA/H/C/005735/II/0126/G</b> BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 26.04.2022.	Positive Opinion adopted by consensus on 26.04.2022.
<b>Darzalex - daratumumab - EMA/H/C/004077/II/0059/G, Orphan</b> Janssen-Cilag International N.V., Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 12.05.2022.	Positive Opinion adopted by consensus on 12.05.2022.
<b>Fasturtec - rasburicase - EMA/H/C/000331/II/0063/G</b> sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 28.04.2022.	Positive Opinion adopted by consensus on 28.04.2022.
<b>Fulphila - pegfilgrastim - EMA/H/C/004915/II/0029</b> Viartis Limited, Rapporteur: Martina Weise Opinion adopted on 19.05.2022.	Positive Opinion adopted by consensus on 19.05.2022.

---

Request for Supplementary Information adopted on 17.03.2022.

---

**Hemlibra - emicizumab -  
EMA/H/C/004406/II/0029/G**

Roche Registration GmbH, Rapporteur:  
Alexandre Moreau

Opinion adopted on 05.05.2022.

Request for Supplementary Information adopted on 17.03.2022.

Positive Opinion adopted by consensus on 05.05.2022.

---

**Ilumetri - tildrakizumab -  
EMA/H/C/004514/II/0029/G**

Almirall S.A, Rapporteur: Jan Mueller-Berghaus  
Opinion adopted on 19.05.2022.

Request for Supplementary Information adopted on 17.03.2022.

Positive Opinion adopted by consensus on 19.05.2022.

---

**IMCIVREE - setmelanotide -  
EMA/H/C/005089/II/0005/G, Orphan**

Rhythm Pharmaceuticals Netherlands B.V.,  
Rapporteur: Karin Janssen van Doorn  
Opinion adopted on 12.05.2022.

Positive Opinion adopted by consensus on 12.05.2022.

---

**Increlex - mecasermin -  
EMA/H/C/000704/II/0076**

Ipsen Pharma, Rapporteur: Outi Mäki-Ikola

Request for Supplementary Information adopted on 28.04.2022.

Request for supplementary information adopted with a specific timetable.

---

**Kanuma - sebelipase alfa -  
EMA/H/C/004004/II/0036/G, Orphan**

Alexion Europe SAS, Rapporteur: Karin Janssen van Doorn

Opinion adopted on 19.05.2022.

Request for Supplementary Information adopted on 07.04.2022.

Positive Opinion adopted by consensus on 19.05.2022.

---

**Lamzede - velmanase alfa -  
EMA/H/C/003922/II/0023/G, Orphan**

Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege

Opinion adopted on 05.05.2022.

Request for Supplementary Information adopted on 03.02.2022.

Positive Opinion adopted by consensus on 05.05.2022.

---

**Lynparza - olaparib -  
EMA/H/C/003726/II/0055/G**

AstraZeneca AB, Rapporteur: Alexandre Moreau

Request for Supplementary Information adopted on 19.05.2022.

Request for supplementary information adopted with a specific timetable.

---

**Ngenla - somatrogon -  
EMA/H/C/005633/II/0001/G, Orphan**

Request for supplementary information adopted with a specific timetable.

---

Pfizer Europe MA EEIG, Rapporteur: Peter Kiely  
Request for Supplementary Information adopted  
on 19.05.2022.

---

**Oncaspar - pegaspargase -**  
**EMA/H/C/003789/II/0045/G** Positive Opinion adopted by consensus on  
05.05.2022.  
Les Laboratoires Servier, Rapporteur: Alexandre  
Moreau  
Opinion adopted on 05.05.2022.

---

**Pedea - ibuprofen -**  
**EMA/H/C/000549/II/0030** Positive Opinion adopted by consensus on  
12.05.2022.  
Recordati Rare Diseases, Rapporteur: Jayne  
Crowe  
Opinion adopted on 12.05.2022.  
Request for Supplementary Information adopted  
on 17.03.2022.

---

**Perjeta - pertuzumab -**  
**EMA/H/C/002547/II/0063** Positive Opinion adopted by consensus on  
28.04.2022.  
Roche Registration GmbH, Rapporteur: Thalia  
Marie Estrup Blicher  
Opinion adopted on 28.04.2022.  
Request for Supplementary Information adopted  
on 17.02.2022.

---

**Privigen - human normal immunoglobulin -**  
**EMA/H/C/000831/II/0185** Request for supplementary information adopted  
with a specific timetable.  
CSL Behring GmbH, Rapporteur: Jan Mueller-  
Berghaus  
Request for Supplementary Information adopted  
on 12.05.2022.

---

**ReFacto AF - moroctocog alfa -**  
**EMA/H/C/000232/II/0163/G** Positive Opinion adopted by consensus on  
05.05.2022.  
Pfizer Europe MA EEIG, Rapporteur: Thalia Marie  
Estrup Blicher  
Opinion adopted on 05.05.2022.

---

**Rixubis - nonacog gamma -**  
**EMA/H/C/003771/II/0044** Request for supplementary information adopted  
with a specific timetable.  
Baxalta Innovations GmbH, Rapporteur: Andrea  
Laslop  
Request for Supplementary Information adopted  
on 12.05.2022.

---

**Ruconest - conestat alfa -**  
**EMA/H/C/001223/II/0071** Positive Opinion adopted by consensus on  
12.05.2022.  
Pharming Group N.V, Rapporteur: Andrea Laslop  
Opinion adopted on 12.05.2022.  
Request for Supplementary Information adopted  
on 17.03.2022.

---

**Senshio - ospemifene -** Positive Opinion adopted by consensus on

---

<p><b>EMA/H/C/002780/II/0042/G</b>  Shionogi B.V., Rapporteur: Paula Boudewina van Hennik  Opinion adopted on 19.05.2022.  Request for Supplementary Information adopted on 10.02.2022.</p>	19.05.2022.
<p><b>Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMA/H/C/004336/II/0053</b>  GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke  Opinion adopted on 12.05.2022.</p>	Positive Opinion adopted by consensus on 12.05.2022.
<p><b>Sivextro - tedizolid phosphate - EMA/H/C/002846/II/0046</b>  Merck Sharp &amp; Dohme B.V., Rapporteur: Bruno Sepodes  Opinion adopted on 19.05.2022.</p>	Positive Opinion adopted by consensus on 19.05.2022.
<p><b>Spikevax - elasmomeran - EMA/H/C/005791/II/0050</b>  Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus  Opinion adopted on 28.04.2022.  Request for Supplementary Information adopted on 24.03.2022.</p>	Positive Opinion adopted by consensus on 28.04.2022.
<p><b>Tysabri - natalizumab - EMA/H/C/000603/II/0132</b>  Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus  Opinion adopted on 19.05.2022.  Request for Supplementary Information adopted on 17.03.2022.</p>	Positive Opinion adopted by consensus on 19.05.2022.
<p><b>Voraxaze - glucarpidase - EMA/H/C/005467/II/0002, Orphan</b>  SERB S.A.S., Rapporteur: Ondřej Slanař  Opinion adopted on 28.04.2022.</p>	Positive Opinion adopted by consensus on 28.04.2022.
<p><b>Vyxeos liposomal - daunorubicin / cytarabine - EMA/H/C/004282/II/0028/G, Orphan</b>  Jazz Pharmaceuticals Ireland Limited, Rapporteur: Johanna Lähteenvuo  Opinion adopted on 12.05.2022.  Request for Supplementary Information adopted on 07.04.2022.</p>	Positive Opinion adopted by consensus on 12.05.2022.
<p><b>Xolair - omalizumab - EMA/H/C/000606/II/0114</b>  Novartis Europharm Limited, Rapporteur: Kristina Dunder</p>	Positive Opinion adopted by consensus on 12.05.2022.

---

Opinion adopted on 12.05.2022.  
Request for Supplementary Information adopted  
on 24.03.2022, 13.01.2022.

---

**ZABDENO - ebola vaccine (rDNA,  
replication-incompetent) -  
EMA/H/C/005337/II/0009/G** Positive Opinion adopted by consensus on  
28.04.2022.  
Janssen-Cilag International N.V., Rapporteur:  
Johann Lodewijk Hillege  
Opinion adopted on 28.04.2022.  
Request for Supplementary Information adopted  
on 17.03.2022.

---

**WS2218/G** Positive Opinion adopted by consensus on  
**Advate-** 12.05.2022.  
**EMA/H/C/000520/WS2218/0115/G**  
**ADYNOVI-**  
**EMA/H/C/004195/WS2218/0029/G**  
Baxalta Innovations GmbH, Lead Rapporteur:  
Jan Mueller-Berghaus  
Opinion adopted on 12.05.2022.  
Request for Supplementary Information adopted  
on 17.03.2022.

---

**WS2225/G** Positive Opinion adopted by consensus on  
**Abseamed-** 05.05.2022.  
**EMA/H/C/000727/WS2225/0097/G**  
**Binocrit-**  
**EMA/H/C/000725/WS2225/0096/G**  
**Epoetin alfa Hexal-**  
**EMA/H/C/000726/WS2225/0096/G**  
Sandoz GmbH, Lead Rapporteur: Alexandre  
Moreau  
Opinion adopted on 05.05.2022.  
Request for Supplementary Information adopted  
on 17.03.2022.

---

**WS2231** Positive Opinion adopted by consensus on  
**Ambirix-** 19.05.2022.  
**EMA/H/C/000426/WS2231/0121**  
**Twinrix Adult-**  
**EMA/H/C/000112/WS2231/0156**  
**Twinrix Paediatric-**  
**EMA/H/C/000129/WS2231/0157**  
GlaxoSmithkline Biologicals SA, Lead  
Rapporteur: Christophe Focke  
Opinion adopted on 19.05.2022.

---

**WS2232/G** Positive Opinion adopted by consensus on  
**Infanrix hexa-** 19.05.2022.  
**EMA/H/C/000296/WS2232/0314/G**

---



---

GlaxoSmithkline Biologicals SA, Lead  
Rapporteur: Christophe Focke  
Opinion adopted on 19.05.2022.

---

**WS2252**  
**Prolia-EMA/H/C/001120/WS2252/0096**  
**XGEVA-EMA/H/C/002173/WS2252/0080**

Amgen Europe B.V., Lead Rapporteur: Kristina  
Dunder  
Opinion adopted on 19.05.2022.

Positive Opinion adopted by consensus on  
19.05.2022.

---

### **B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects**

---

**Adakveo - crizanlizumab -**  
**EMA/H/C/004874/II/0007, Orphan**

Novartis Europharm Limited, Rapporteur:  
Daniela Philadelphia, "Update of section 5.2 of  
the SmPC in order to update pharmacokinetic  
information based on the results from PK  
reanalysis. In addition, the MAH took the  
opportunity to introduce minor editorial changes  
to the SmPC."

Request for Supplementary Information adopted  
on 12.05.2022.

Request for supplementary information adopted  
with a specific timetable.

---

**Avonex - interferon beta-1a -**  
**EMA/H/C/000102/II/0192**

Biogen Netherlands B.V., Rapporteur: Maria  
Concepcion Prieto Yerro, "Update of section 4.4  
of the SmPC in order to add a new warning  
regarding the risk of injection site necrosis  
based on post-marketing experience. The  
Package Leaflet is updated accordingly. In  
addition, the MAH took the opportunity to  
update the list of local representatives in the  
Package Leaflet."

Request for Supplementary Information adopted  
on 12.05.2022.

Request for supplementary information adopted  
with a specific timetable.

---

**AYVAKYT - avapritinib -**  
**EMA/H/C/005208/II/0014, Orphan**

Blueprint Medicines (Netherlands) B.V.,  
Rapporteur: Blanca Garcia-Ochoa, "Submission  
of the final report from study BLU-285-1101  
listed as a Specific Obligation in the Annex II of  
the Product Information. This is an  
interventional Phase 1 study, designed to  
evaluate the safety, tolerability, PK,  
pharmacodynamics, and preliminary  
antineoplastic activity of avapritinib

Positive Opinion adopted by consensus on  
12.05.2022.

---

administered orally in patients with unresectable GIST or other relapsed or refractory solid tumours. The Annex II is updated accordingly.”  
Opinion adopted on 12.05.2022.  
Request for Supplementary Information adopted on 10.02.2022.

---

**Biktarvy - bictegrovir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/II/0047**

Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, “Update of sections 4.8 and 5.1 of the SmPC in order to include efficacy and safety data for antiretroviral therapy (ART)-naive adults based on final results from interventional studies GS-US-380-1489 (A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults) and GS-US-380-1490 (A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults).  
In addition, the MAH took this opportunity to introduce some minor administrative updates.”  
Request for Supplementary Information adopted on 05.05.2022.

Request for supplementary information adopted with a specific timetable.

---

**Cimzia - certolizumab pegol - EMEA/H/C/001037/II/0101**

UCB Pharma S.A., Rapporteur: Kristina Dunder, “C.I.4: Update of section 4.6 of the SmPC in order to update information on pregnancy based on non-interventional data from the UCB Global Safety Database on prospective Cimzia-exposed pregnancies with known outcomes; the Package Leaflet is updated accordingly.”  
Request for Supplementary Information adopted on 19.05.2022, 17.02.2022, 11.11.2021.

Request for supplementary information adopted with a specific timetable.

---

**Cotellic - cobimetinib - EMEA/H/C/003960/II/0025**

Roche Registration GmbH, Rapporteur: Filip Josephson, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC based on final results from study GO29665 (iMATRIX\_cobimetinib) which corresponds to study 4 of PIP P/0119/2021. This

Positive Opinion adopted by consensus on 19.05.2022.

---

is a phase I/II, multicentre, open-label, dose-escalation study of the safety, efficacy and pharmacokinetics of cobimetinib in paediatric and young adult patients with previously treated solid tumours. The section 2 of the Package Leaflet is updated accordingly.”

Opinion adopted on 19.05.2022.

Request for Supplementary Information adopted on 31.03.2022.

---

**Fabrazyme - agalsidase beta -  
EMA/H/C/000370/II/0123**

Positive Opinion adopted by consensus on 19.05.2022.

Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.2 and 6.6 of the SmPC in order to modify administration instructions based on pre-existing data from the clinical trials AGAL-01-002-98, AGAL-005-99, AGAL-008-00, AGAL-02503 and AGAL-016-01 that already serve as the basis for the currently approved SmPC. In addition, section 5.1 of the SmPC is updated in order to add further information on Fabry patients included in the clinical trials. The Package Leaflet is updated accordingly.”

Opinion adopted on 19.05.2022.

Request for Supplementary Information adopted on 10.02.2022.

---

**Fasenra - benralizumab -  
EMA/H/C/004433/II/0041**

Positive Opinion adopted by consensus on 19.05.2022.

AstraZeneca AB, Rapporteur: Fátima Ventura, “Update of section 5.1 of the SmPC in order to include efficacy information based on the final results from study D3250C00065 (PONENTE); this is a multicenter, open-label, Phase IIIb efficacy and safety study of benralizumab 30 mg administered subcutaneously to reduce oral corticosteroid use in adult patients with severe eosinophilic asthma on high-dose inhaled corticosteroid plus long-acting  $\beta$ 2 agonist and chronic oral corticosteroid therapy. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

Opinion adopted on 19.05.2022.

Request for Supplementary Information adopted on 27.01.2022.

---

**IMCIVREE - setmelanotide -  
EMA/H/C/005089/II/0006, Orphan**

Positive Opinion adopted by consensus on 12.05.2022.

Rhythm Pharmaceuticals Netherlands B.V., Rapporteur: Karin Janssen van Doorn, “Submission of the final report from study RM-

---

---

493-011 "Setmelanotide (RM-493) Treatment Trial in Patients with Rare Genetic Disorders of Obesity". This is a Phase 2, open-label, uncontrolled, non-randomized study with an additional long-term safety extension. The primary objective was to assess changes in body weight within each patient population with rare genetic disorders of obesity (POMC, LEPR, BBS and AS) following 3-months of setmelanotide treatment."

Opinion adopted on 12.05.2022.

---

**Jardiance - empagliflozin -  
EMA/H/C/002677/II/0062/G**

Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC with the results of clinical study EMPULSE (1245-0204), a multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initiated in patients hospitalised for acute heart failure (de novo or decompensated chronic HF) who have been Stabilised (EMPULSE)."

In addition, the MAH took the opportunity to implement editorial changes in the SmPC."

Request for Supplementary Information adopted on 28.04.2022, 10.02.2022.

Request for supplementary information adopted with a specific timetable.

---

**JEMPERLI - dostarlimab -  
EMA/H/C/005204/II/0009**

GlaxoSmithKline (Ireland) Limited, Rapporteur: Blanca Garcia-Ochoa, "Type II (C.I.4) - To update section 6.6 of the SmPC to include the requirement to use an in-line filter during finished product administration, to amend the administration equipment compatibilities and to provide additional administration dilution instructions. The Package Leaflet is updated accordingly."

In addition, the Applicant took the opportunity to correct a typographical error from SmPC section 5.1 Pharmacodynamic properties."

Opinion adopted on 28.04.2022.

Positive Opinion adopted by consensus on 28.04.2022.

---

**Luminity - perflutren -  
EMA/H/C/000654/II/0039**

Lantheus EU Limited, Rapporteur: Peter Kiely, "Update of section 4.4 of the SmPC in order to add a new warning on sickle cell anaemia, and

Positive Opinion adopted by consensus on 19.05.2022.

---

update of section 4.8 of the SmPC to include the new ADRs Kounis Syndrome, sickle cell anaemia and vaso-occlusive crisis based on reports in the post-marketing setting.  
The Package Leaflet is updated accordingly.”  
Opinion adopted on 19.05.2022.

---

**Myozyme - alglucosidase alfa -  
EMA/H/C/000636/II/0090**

Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault, “Submission of the final report from non-interventional PASS Pompe Safety Sub-Registry - AGLU06909/LTS13930. This final study report is submitted to address the assessment report conclusion of the Pompe registry report 2020 (MEA024.15 and MEA025.15 Annual Pompe Registry Report 2020).”

Request for Supplementary Information adopted on 05.05.2022.

Request for supplementary information adopted with a specific timetable.

---

**Ocaliva - obeticholic acid -  
EMA/H/C/004093/II/0030, Orphan**

Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, “Update of section 4.3 of the SmPC in order to include contraindication in patients with decompensated cirrhosis (e.g., Child-Pugh Class B or C) or a prior decompensation event based on the MAH's conclusion that it will not be feasible to establish the safety and efficacy of Ocaliva in these patients from either of the ongoing studies 747-302 and 747-401 listed as Specific Obligations in Annex II. Consequently, dosing instructions for patients with CP-B and CP-C cirrhosis are no longer applicable and section 4.2 has been updated accordingly.

In addition, section 4.4 of the SmPC to include a new warning on monitoring and management of patients for possible progression of PBC and other hepatic adverse reactions.

The MAH also took the opportunity to remove the outdated term “primary biliary cirrhosis” from section 4.1 and to make editorial changes to sections 4.8, 4.9, 5.1 and Annex IIE to improve clarity and correct typographical errors. The Package Leaflet is updated accordingly. Furthermore, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2”

Request for Supplementary Information adopted

---

Positive Opinion adopted by consensus on 19.05.2022.

See 9.1

---

on 24.02.2022, 16.12.2021, 16.09.2021.  
Opinion adopted on 19.05.2022.

---

**Opsumit - macitentan -  
EMA/H/C/002697/II/0043, Orphan**

Janssen-Cilag International N.V., Rapporteur:  
Maria Concepcion Prieto Yerro, "Update of sections 4.2 and 4.4 of the SmPC to remove a sentence and a warning on the limited clinical experience in patients over the age of 75 years, following the recommendation of the EMA/H/C/PSUSA/00010115/202010 procedure to remove 'Elderly patients' as missing information in the RMP. The Package Leaflet is being updated accordingly. In addition, the MAH took this opportunity to update the Package Leaflet to include a section on Male fertility and align it with the currently approved information in SmPC, sections 4.6 Fertility, pregnancy and lactation and 5.3 Preclinical safety."

Opinion adopted on 28.04.2022.  
Request for Supplementary Information adopted on 11.11.2021.

Positive Opinion adopted by consensus on 28.04.2022.

---

**Orladeyo - berotralstat -  
EMA/H/C/005138/II/0006**

BioCryst Ireland Limited, Rapporteur: Peter Kiely, "Update of sections 4.4 and 4.5 of the SmPC in order to remove the warning for women of childbearing potential and amend drug-drug interaction information with desogestrel based on final results from study BCX7353-111; this is a phase 1 drug interaction study to evaluate the effects of berotralstat on the pharmacokinetics of a combination oral contraceptive, desogestrel with ethinyl estradiol; the Package Leaflet is updated accordingly."

Request for Supplementary Information adopted on 12.05.2022.

Request for supplementary information adopted with a specific timetable.

---

**Orphacol - cholic acid -  
EMA/H/C/001250/II/0044, Orphan**

Laboratoires CTRS, Rapporteur: Anastasia Mountaki, "Update of sections 4.3 and 4.5 of the SmPC in order to extend the currently existing contra-indication with phenobarbital in order to include primidone based on scientific literature. The Package Leaflet is updated accordingly. In addition, the MAH is taking this opportunity to submit a combined SmPC for both dosages, 50 mg and 250 mg and to introduce editorial

Positive Opinion adopted by consensus on 19.05.2022.

See 9.1

---

changes and update the contact details of the local representatives in the Package Leaflet.”  
Request for Supplementary Information adopted on 24.03.2022.  
Opinion adopted on 19.05.2022.

---

<p><b>Orphacol - cholic acid - EMA/H/C/001250/II/0045, Orphan</b> Laboratoires CTRS, Rapporteur: Anastasia Mountaki, “Update of section 4.5 of the SmPC in order to update the existing information regarding concomitant use of cholic acid (the active substance of Orphacol) and ursodeoxycholic acid based on scientific literature. The Package Leaflet is updated accordingly.” Request for Supplementary Information adopted on 24.03.2022. Opinion adopted on 19.05.2022.</p>	<p>Positive Opinion adopted by consensus on 19.05.2022.  See 9.1</p>
---	--

---

<p><b>Regkirona - regdanvimab - EMA/H/C/005854/II/0004</b> Celltrion Healthcare Hungary Kft., Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC to include in vitro neutralisation activity of regdanvimab against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern based on report REP-ND22-047.” Opinion adopted on 19.05.2022.</p>	<p>Positive Opinion adopted by consensus on 19.05.2022.</p>
--	---

---

<p><b>Repatha - evolocumab - EMA/H/C/003766/II/0058</b> Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, “C.I.4 Update to section 5.1 of the SmPC following the results of interventional study 20160184. It was a double-blind, placebo-controlled, randomized study evaluating the effect of evolocumab on coronary atherosclerotic plaques as assessed by optical coherence tomography (OCT) following 50 weeks of treatment in subjects with non-ST-elevation acute coronary syndrome (NSTEMI-ACS) who take maximally tolerated statin therapy.” Opinion adopted on 28.04.2022. Request for Supplementary Information adopted on 17.02.2022.</p>	<p>Positive Opinion adopted by consensus on 28.04.2022.</p>
---	---

---

<p><b>Revatio - sildenafil - EMA/H/C/000638/II/0098</b> Upjohn EESV, Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.8 and 5.1 to</p>	<p>Positive Opinion adopted by consensus on 28.04.2022.</p>
--	---

---

---

include long-term safety data in adults for the approved dose, and evidence of safe and effective use in adults in higher than recommended doses, based on study A1481324; a multinational, multicentre randomized, double-blind, parallel-group study in 385 adults with Pulmonary Arterial Hypertension (PAH) undertaken to assess the effects of different dose levels of oral sildenafil on mortality. In addition, the MAH took the opportunity to implement editorial changes in the SmPC.”

Opinion adopted on 28.04.2022.

Request for Supplementary Information adopted on 16.12.2021.

---

**Samsca - tolvaptan -  
EMA/H/C/000980/II/0046/G**

Positive Opinion adopted by consensus on 12.05.2022.

Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Armando Genazzani, “Update of section 4.5 of the SmPC in order to include information on the transporter substrates P-glycoprotein, BCRP and OCT1 upon request by PRAC following the assessment of PSUSA/00002994/202105 based on final results from the drug-drug interaction studies 156-201-00233 and 156-201-00234 (to align with the Jinarc PI); the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

Opinion adopted on 12.05.2022.

---

**Spikevax - elasmomeran -  
EMA/H/C/005791/II/0057**

Request for supplementary information adopted with a specific timetable.

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, “Update of section 4.2 of the Spikevax SmPC to include a 50 µg booster dose for adolescents 12 to 18 years of age, based on the extrapolation of safety and efficacy data from young adults (18 to 24 years of age). The package leaflet is updated accordingly.”

Request for Supplementary Information adopted on 19.05.2022, 22.04.2022.

See 9.1

---

**Spravato - esketamine -  
EMA/H/C/004535/II/0012**

Positive Opinion adopted by consensus on 12.05.2022.

Janssen-Cilag International N.V., Rapporteur: Martina Weise, “Update to the SmPC section 4.2 and section 5.1, based on the findings in Chinese subjects from a recently completed efficacy Phase 3 study in adult with treatment-



---

resistant depression.”  
Opinion adopted on 12.05.2022.  
Request for Supplementary Information adopted  
on 10.02.2022.

---

**Tasigna - nilotinib -**

**EMA/H/C/000798/II/0115/G**

Novartis Europharm Limited, Rapporteur: Thalia Marie Estrup Blicher, “C.I.4: Update of section 4.8 of the SmPC in order to update the ADRs frequency category based on pooled safety data from 13 interventional clinical studies, 5 of which have not been previously assessed (CAMN107A2303 - 120 months data; CAMN107A2404; CAMN107E2401; CAMN107ECN02 and CAMN107EIC01).

In addition, the MAH took the opportunity to merge the current 2 SmPCs (one for 150 mg and one for 50 mg/200 mg) into one single SmPC, by including all information from the 150 mg SmPC into the 50 mg/200 mg SmPC; and to implement editorial changes. The Package Leaflet is proposed to be updated accordingly.

A.6: Update of nilotinib ATC code based on the last update of the WHO ATC index.”

Opinion adopted on 19.05.2022.

Positive Opinion adopted by consensus on 19.05.2022.

---

**Tygacil - tigecycline -**

**EMA/H/C/000644/II/0121**

Pfizer Europe MA EEIG, Rapporteur: Blanca Garcia-Ochoa, “Update of section 5.1 of the SmPC in order to reflect updated breakpoint tables regarding antimicrobial susceptibility testing (EUCAST).

In addition, the MAH is taking the opportunity to update section 4.6 of the SmPC to remove reference to “pharmacodynamic/toxicological” data and update the contact details of the local representatives in the Package Leaflet.”

Request for Supplementary Information adopted on 19.05.2022.

Request for supplementary information adopted with a specific timetable.

See 9.1

---

**Vaborem - meropenem / vaborbactam -**

**EMA/H/C/004669/II/0010/G**

Menarini International Operations Luxembourg S.A., Rapporteur: Filip Josephson, “A grouped application including 8 type II variations (C.I.4) and 1 type II variation (C.I.13):

Update of section 4.5 of the SmPC based on the results of a series of non-clinical drug-drug interaction studies undertaken with vaborbactam or meropenem. The Package

Positive Opinion adopted by consensus on 19.05.2022.

---

Leaflet has been updated accordingly. In addition, the MAH has submitted non-clinical data on the phototoxicity potential of meropenem from a 3T3 neutral red uptake phototoxicity test.”

Opinion adopted on 19.05.2022.

Request for Supplementary Information adopted on 17.02.2022, 25.11.2021, 11.03.2021.

---

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0052**

AstraZeneca AB, Rapporteur: Sol Ruiz, “Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a booster dose of Vaxzevria (homologous or heterologous) based on interim immunogenicity and safety data from the pivotal study D7220C00001, a partially double-blinded, randomised, multinational, active-controlled phase II/III clinical study and supportive literature evidence from studies COV001, RHH-001, COV-BOOST and Com-COV studies. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes/corrections throughout the product information.”

Request for Supplementary Information adopted on 22.04.2022.

Opinion adopted on 19.05.2022.

---

Positive Opinion adopted by consensus on 19.05.2022.

See 9.1

**Veltassa - patiromer - EMEA/H/C/004180/II/0029**

Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, “Update of sections 4.2 and 4.5 of the SmPC in order to introduce new drug-drug interaction information based on results from four in vitro studies: RLY-TR-0174, titled “In Vitro Evaluation of Potential RLY5016S and Immunosuppressant Drug-Drug Interactions”; RLY-TR-0184 (titled “In Vitro Evaluation of Potential Drug-Drug Interactions Between Patiromer and Sevelamer Hydrochloride”); “In Vitro Evaluation of Drug-Drug Interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS” and “Drug-drug interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS in a simulated GI tract passage study”. The Package Leaflet is updated accordingly.”

---

Request for supplementary information adopted with a specific timetable.

---

Request for Supplementary Information adopted on 19.05.2022.

---

**Vidaza - azacitidine -  
EMA/H/C/000978/II/0057**

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik, "Update of section 4.2 of the SmPC in order to include a statement advising health care professionals not to interchange azacitidine formulations (injectable versus oral), and update section 4.6 of the SmPC to revise the recommended duration of contraception use for women and men. The Package Leaflet is updated accordingly."  
Opinion adopted on 28.04.2022.

Positive Opinion adopted by consensus on 28.04.2022.

---

**VPRIV - velaglucerase alfa -  
EMA/H/C/001249/II/0054, Orphan**

Takeda Pharmaceuticals International AG, Rapporteur: Martina Weise, "Submission of the final report from study SHP-GCB-402: a multicentre, open-label, single-arm, phase 4 study designed to prospectively evaluate the effects of VPRIV on bone-related pathology in treatment-naïve subjects with type 1 Gaucher disease."  
Request for Supplementary Information adopted on 28.04.2022.

Request for supplementary information adopted with a specific timetable.

---

**Vyxeos liposomal - daunorubicin /  
cytarabine - EMA/H/C/004282/II/0030,  
Orphan**

Jazz Pharmaceuticals Ireland Limited, Rapporteur: Johanna Lähteenvuo, "Update of sections 4.2, 4.4 and 5.2 of the SmPC to amend information and delete the existing warning for patients with renal impairment based on the final results from study CPX351-102 (PMR2): a phase 1, open-label, PK and safety study to evaluate the potential impact of renal impairment on the pharmacokinetics and safety of CPX-351 (Daunorubicin and Cytarabine) liposome for injection treatment in adult patients with hematologic malignancies."  
Request for Supplementary Information adopted on 12.05.2022.

Request for supplementary information adopted with a specific timetable.

---

**WS2244  
Nuwiq-EMA/H/C/002813/WS2244/0048  
Vihuma-  
EMA/H/C/004459/WS2244/0030**

Octapharma AB, Lead Rapporteur: Jan Mueller-

---

Request for supplementary information adopted with a specific timetable.

---

---

Berghaus, "Update of sections 4.8 and 5.1 of the SmPC in order to add safety and efficacy data based on the final CSR from the category 3 study GENA-21b; a prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalised prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemophilia A. Further, upon request by the CHMP following the assessment of study GENA-05 (P46 013 and P46 014), the MAH is updating the numbers of evaluated subjects in SmPC section 4.8 and is removing of the sentence "A prospective open-label clinical study in PUPs with severe haemophilia A (<1% FVIII:C) is ongoing" in section 5.1 of the SmPC. The Package Leaflet is updated accordingly."

Request for Supplementary Information adopted on 05.05.2022.

---

**WS2250**

**Prezista-**

**EMA/H/C/000707/WS2250/0116**

**Rezolsta-**

**EMA/H/C/002819/WS2250/0046**

**Symtuza-**

**EMA/H/C/004391/WS2250/0043**

Janssen-Cilag International N.V., Lead Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.3 and 4.5 of the SmPC in order to update the safety information based on final results from study TMC114FD1HTX1002; this is an interventional phase 1, 2-Panel, Fixed-Sequence, Open-Label Single-Center Study to Assess the Effect of Single and Multiple Doses of Darunavir in Combination with Cobicistat or Ritonavir on the Pharmacokinetics of Single Dose Dabigatran Etexilate in Healthy Participants. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes in order to update the contact details of the local representatives in the Package Leaflet." Opinion adopted on 19.05.2022.

Positive Opinion adopted by consensus on 19.05.2022.

---

**WS2253**

**Eucreas-**

**EMA/H/C/000807/WS2253/0096**

**Galvus-EMA/H/C/000771/WS2253/0076**

**Icandra-**

**EMA/H/C/001050/WS2253/0100**

---

Request for supplementary information adopted with a specific timetable.

---

**Jalra-EMA/H/C/001048/WS2253/0078**  
**Xiliarx-EMA/H/C/001051/WS2253/0077**  
**Zomarist-**

**EMA/H/C/001049/WS2253/0098**

Novartis Europharm Limited, Lead Rapporteur:  
Kristina Dunder, Lead PRAC Rapporteur: Annika  
Folin, "Update of section 4.8 of the SmPC in  
order to add the new ADRs 'cutaneous  
vasculitis'."

Request for Supplementary Information adopted  
on 05.05.2022.

---

### **B.5.3. CHMP-PRAC assessed procedures**

---

**Alecensa - alectinib -**  
**EMA/H/C/004164/II/0037/G**

Roche Registration GmbH, Rapporteur: Filip  
Josephson, PRAC Rapporteur: Jana  
Lukacisinova, "Update of sections 4.2, 4.4 and  
4.8 of the SmPC in order to add a new warning,  
dose modification advice and description of the  
known ADR haemolytic anaemia based on an  
updated Drug Safety Report; the Package  
Leaflet is updated accordingly. In addition, the  
MAH took the opportunity to introduce editorial  
updates in the Maltese and Romanian product  
information. Moreover, the ATC code for  
alectinib is being updated from L01XE36 to  
L01ED03."

Request for Supplementary Information adopted  
on 19.05.2022, 27.01.2022.

Request for supplementary information adopted  
with a specific timetable.

---

**Apexxnar - pneumococcal polysaccharide**  
**conjugate vaccine (20-valent, adsorbed) -**  
**EMA/H/C/005451/II/0002**

Pfizer Europe MA EEIG, Rapporteur: Daniela  
Philadelphly, PRAC Rapporteur: Jean-Michel  
Dogné, "Update of sections 4.5, 4.8 and 5.1 of  
the SmPC to add information regarding the co-  
administration of Apexxnar with seasonal  
quadrivalent influenza vaccine (QIV) based on  
final study results from study B7471004, "A  
Phase 3, Randomized, Double-Blind Trial to  
Evaluate the Safety and Immunogenicity of a 20  
valent Pneumococcal Conjugate Vaccine  
(20vPnC) When Coadministered with Seasonal  
Inactivated Influenza Vaccine (SIIV) in Adults  
≥65 Years of Age." listed as a category 3 study  
in the RMP.

Request for supplementary information adopted  
with a specific timetable.

---

---

The Package Leaflet is updated accordingly.  
The updated RMP version 1.1 has also been submitted.”  
Request for Supplementary Information adopted on 19.05.2022.

---

**ASPAVELI - pegcetacoplan - EMEA/H/C/005553/II/0002, Orphan**  
Swedish Orphan Biovitrum AB (publ),  
Rapporteur: Alexandre Moreau, PRAC  
Rapporteur: Kimmo Jaakkola, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC based on final results from study APL2-302 (Pegasus) listed as a category 3 study in the RMP; this is a global, Phase 3, prospective, randomised, multicentre, open-label, active-comparator-controlled study in 80 subjects. The objective was to confirm treatment efficacy and safety of pegcetacoplan monotherapy for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The submission of this study addresses MEA 001. The Package Leaflet is updated accordingly. The RMP version 1.0 has been agreed.”  
Opinion adopted on 19.05.2022.  
Request for Supplementary Information adopted on 24.03.2022.

Positive Opinion adopted by consensus on 19.05.2022.

---

**Caprelsa - vandetanib - EMEA/H/C/002315/II/0043**  
Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, “C.I.4 Update of section 5.1 of the SmPC in order to update pharmacodynamic information based on interim results from study D4200C00104, listed as a specific obligation in the Annex II. This is an observational study (including a retrospective arm to evaluate the Benefit/Risk of vandetanib (Caprelsa) 300 mg in RET mutation negative and RET mutation positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic thyroid cancer (MTC)), to confirm the efficacy and safety of Caprelsa in RET-negative patients with the aim to fulfil SOB001 and convert Caprelsa from conditional to normal Marketing Authorisation.  
In addition, the MAH takes to opportunity to rectify the Dutch translation of the Caprelsa Product Information.”  
Request for Supplementary Information adopted

Request for supplementary information adopted with a specific timetable.

See 9.1

---

on 19.05.2022, 16.12.2021, 24.06.2021,  
28.05.2020.

---

**Defitelio - defibrotide -**

**EMA/H/C/002393/II/0056, Orphan**

Gentium S.r.l., Rapporteur: Kristina Dunder,  
PRAC Rapporteur: Ulla Wändel Liminga,  
"Submission of the final report from study 15-007 listed as a specific obligation in the Annex II of the Product Information. This is a phase 3, randomised, adaptive study (15-007) of Defibrotide vs. best supportive care in the prevention of hepatic veno-occlusive disease in adult and paediatric patients undergoing hematopoietic stem cell transplant (HSCT). The RMP version 9 has also been submitted. The MAH has also taken the opportunity to align the PI to the latest QRD template 10.2 which replaces the United Kingdom with United Kingdom (Northern Ireland) in the PIL. In addition, the MAH is correcting the following errata during the linguistic review of the PI: correction of the paragraph number for Regulation (EC) No 726.2004 which was cited incorrectly in Annex II of the French PI and formatting updates to Norwegian and Swedish language PIs."

Opinion adopted on 19.05.2022.

Request for Supplementary Information adopted on 10.03.2022, 28.10.2021, 08.07.2021.

---

Positive Opinion adopted by consensus on 19.05.2022.

See 9.1

**Delyba - delamanid -**

**EMA/H/C/002552/II/0053, Orphan**

Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, PRAC Rapporteur: Jean-Michel Dogné, "Update of section 4.8 of the SmPC in order to update the list of adverse drug reactions (ADRs table) following the development of an improved methodology to identify relevant ADRs likely attributable to delamanid. The section 4 of the Package Leaflet is updated accordingly. The RMP version 3.6 has also been submitted."

Request for Supplementary Information adopted on 05.05.2022, 13.01.2022.

---

Request for supplementary information adopted with a specific timetable.

**Dexdor - dexmedetomidine -**

**EMA/H/C/002268/II/0035**

Orion Corporation, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 4.4 of the SmPC and PL section 2 in order to add a new warning on increased

---

Positive Opinion adopted by consensus on 19.05.2022.

---

mortality in ICU patients ≤65 years old, based on results from study SPICE III (randomised controlled trial) and following the assessment of the post-authorisation measure LEG 16.4. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.

The RMP version 9.1, a DHPC and communication plan have also been agreed.”

Opinion adopted on 19.05.2022.

Request for Supplementary Information adopted on 24.03.2022.

---

**Enbrel - etanercept -  
EMA/H/C/000262/II/0246**

Positive Opinion adopted by consensus on 05.05.2022.

Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, “Update of section 5.1 of the Summary of product characteristics (SmPC) in order to update clinical information based on final results obtained from the clinical paediatric study B1801023 (CLIPPER 2). Also, the Risk management plan (RMP) was brought up to date with version 7.6.”

Opinion adopted on 05.05.2022.

Request for Supplementary Information adopted on 13.01.2022.

---

**GIVLAARI - givosiran -  
EMA/H/C/004775/II/0006, Orphan**

Positive Opinion adopted by consensus on 05.05.2022.

Alnylam Netherlands B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, “Update of SmPC section 4.8 to add 'blood homocysteine increase' as a new ADR with the frequency 'common' and SmPC section 4.4 to add a related warning. The Package Leaflet is being updated accordingly. In addition, the MAH took the opportunity to update the contact details of the local representatives for Malta and Cyprus in the Package Leaflet.

An updated RMP version 1.4 was agreed during the procedure: consequences of blood homocysteine increase is being added as a new important potential risk, the clinical and post-marketing exposure is being updated and the due dates for ALN-AS1-002 and ALN-AS1-003 final study reports are being revised.”

Opinion adopted on 05.05.2022.

Request for Supplementary Information adopted on 10.03.2022, 13.01.2022, 28.10.2021,



---

02.09.2021.

**Imbruvica - ibrutinib -  
EMA/H/C/003791/II/0069**

Janssen-Cilag International N.V., Rapporteur:  
Filip Josephson, PRAC Rapporteur: Nikica  
Mirošević Skvrce, "Update of the SmPC section  
4.4 to include information on fatal and serious  
cardiac arrhythmias and cardiac failure, relevant  
warnings and periodical monitoring of patients-  
following a safety assessment for increased risk  
of sudden death/cardiac death with the use of  
ibrutinib. Section 2 of the PL has been updated  
accordingly. Typographical errors have been  
corrected throughout the PI. The revised RMP  
version 11 has been submitted."

Request for Supplementary Information adopted  
on 19.05.2022, 27.01.2022.

Request for supplementary information adopted  
with a specific timetable.

---

**Jorveza - budesonide -  
EMA/H/C/004655/II/0015, Orphan**

Dr. Falk Pharma GmbH, Rapporteur: Martina  
Weise, PRAC Rapporteur: Zane Neikena,  
"Update of section 4.8 of the SmPC in order to  
update the list of adverse reactions based on  
final results from the long-term maintenance  
study BUL-2/EER; this is a double-blind,  
randomized, placebo-controlled, phase III study  
on the efficacy and tolerability of a 48-week  
treatment with two different doses of  
budesonide effervescent tablets vs. placebo for  
maintenance of clinico-pathological remission in  
adult patients with eosinophilic esophagitis. The  
Package Leaflet is updated accordingly. In  
addition, the MAH took the opportunity to  
update the list of local representatives in the  
Package Leaflet. The RMP version 3.0 has also  
been submitted. The MAH also submitted the  
final report of study BUL-6/BIO, which was  
previously assessed within the scope of  
extension EMA/H/C/004655/X/0007/G as  
applicant's response to CHMP Day 120 List of  
Questions."

Request for Supplementary Information adopted  
on 19.05.2022.

Request for supplementary information adopted  
with a specific timetable.

---

**Kaftrio - ivacaftor / tezacaftor /  
elxacaftor -  
EMA/H/C/005269/II/0017/G, Orphan**

Vertex Pharmaceuticals (Ireland) Limited,  
Rapporteur: Johann Lodewijk Hillege, PRAC  
Rapporteur: Martin Huber, "C.I.4

Request for supplementary information adopted  
with a specific timetable.

---

Update of section 5.3 of the SmPC in order to update the non-clinical information based on final results from a 2-year oral carcinogenicity study in rats (VX-445-TX-015) evaluating the carcinogenic potential of up to 10 mg/kg/day of elxacaftor. An updated RMP (version 6.0) has also been submitted to include the completion of the 2-year carcinogenicity study in rats as well as to update the post-market pregnancy safety information collection form following EMEA/H/C/WS2048.

C.I.13

To submit the final report of Tezacaftor Juvenile Toxicity study (VX-661-TX-038)."

Request for Supplementary Information adopted on 05.05.2022, 10.02.2022.

---

**Mylotarg - gemtuzumab ozogamicin - EMEA/H/C/004204/II/0024, Orphan**

Pfizer Europe MA EEIG, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of sections 4.8, 5.1 and 5.2 of the SmPC based on the final results from study B176103; this is a single-arm, open-label, phase 4 study evaluating the QT interval, pharmacokinetics, and safety of gemtuzumab ozogamicin as a single-agent regimen in patients with relapsed or refractory CD33-positive Acute Myeloid Leukaemia. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to introduce some editorial changes in the product information."

Request for Supplementary Information adopted on 19.05.2022, 18.03.2022.

Request for supplementary information adopted with a specific timetable.

---

**Neofordex - dexamethasone - EMEA/H/C/004071/II/0017/G**

Laboratoires CTRS, Rapporteur: Ondřej Slanař, PRAC Rapporteur: Tiphaine Vaillant"1. C.I.11.z (Type IB): To update the RMP for Neofordex to version 4.3 with a completion of category 3 activity 'Removal of the score line for sub-division of the 40 mg tablet, and consequent deletion of the 20 mg posology' and to include the Direct Healthcare Professional Communication (DHPC);

"

Request for Supplementary Information adopted on 05.05.2022.

Request for supplementary information adopted with a specific timetable.

---

**Pemazyre - pemigatinib -**

Positive Opinion adopted by consensus on

---

<p><b>EMA/H/C/005266/II/0005, Orphan</b>  Incyte Biosciences Distribution B.V.,  Rapporteur: Alexandre Moreau, PRAC  Rapporteur: Menno van der Elst, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final results from study INCB054828 (FIGHT-202) listed as a specific obligation in the Annex II (SOB/002); this is a phase 2 study investigating the efficacy and safety of pemigatinib in adults with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy. The Annex II has been updated accordingly. RMP version 2.0 has also been submitted."  Opinion adopted on 19.05.2022.  Request for Supplementary Information adopted on 24.03.2022.</p>	<p>19.05.2022.</p>
<p><b>Ryeqo - relugolix / estradiol / norethisterone acetate - EMA/H/C/005267/II/0006</b>  Gedeon Richter Plc., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, "Submission of the final report from study MVT-601-035 listed as a category 3 study in the RMP. This is an international phase III double-blind, placebo-controlled, randomised withdrawal study of relugolix co-administered with estradiol and norethisterone in women with heavy menstrual bleeding associated with uterine fibroids to evaluate the efficacy and safety of long-term use of this medicinal product. The RMP version 1.0 has also been submitted."  Opinion adopted on 05.05.2022.  Request for Supplementary Information adopted on 10.03.2022.</p>	<p>Positive Opinion adopted by consensus on 05.05.2022.</p>
<p><b>Uptravi - selexipag - EMA/H/C/003774/II/0034</b>  Janssen-Cilag International N.V., Rapporteur: Martina Weise, PRAC Rapporteur: Nathalie Gault, "Update of sections 4.8 and 5.1 of the SmPC to add dyspepsia as a new ADR with frequency common, and to include further information on the frequency of dyspepsia and on haemoglobin decrease in patients receiving triple combination therapy, and to add efficacy and mortality data of initial triple combination treatment with selexipag, macitentan and</p>	<p>Positive Opinion adopted by consensus on 19.05.2022.</p>

---

tadalafil in newly diagnosed PAH patients compared to initial double combination treatment with placebo, macitentan and tadalafil, based on the studies AC-065A308 (TRITON) and AC-065A404 (TRACE). AC-065A308 (TRITON) study was a randomized, double-blind, placebo-controlled, parallel-group, Phase 3b, efficacy and safety study comparing triple oral combination therapy (selexipag, macitentan, tadalafil) with double oral combination therapy (placebo, macitentan, tadalafil) in newly diagnosed, treatment-naïve participants with PAH. The AC-065A404 (TRACE) study was a randomized, double-blind, placebo-controlled, parallel-group, exploratory Phase 4 study in participants with PAH to assess the effect of selexipag on daily life physical activity and participant's self-reported symptoms and their impacts. The package leaflet is updated accordingly. A revised RMP version 9.2 was provided as part of the application."

Opinion adopted on 19.05.2022.

Request for Supplementary Information adopted on 02.12.2021.

---

**XOSPATA - gilteritinib -**

**EMA/H/C/004752/II/0007, Orphan**

Astellas Pharma Europe B.V., Rapporteur: Ingrid Wang, PRAC Rapporteur: Martin Huber, "Submission of the report of an integrated analysis to demonstrate the safety of long-term treatment with gilteritinib when all patients enrolled in studies 2215-CL-0101, 2215-CL-0102 and 2215-CL-0301 have completed at least 3 years of treatment with gilteritinib or have withdrawn prior to completing at least 3 years of treatment.

The studies refer to: 1) study 2215-CL-0101: a phase 1/2 open-label, dose escalation study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASP2215 (gilteritinib) in patients with relapsed or refractory acute myeloid leukaemia (AML); 2) study 2215-CL-0102: a phase 1 open-label, dose escalation study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASP2215 in Japanese patients with relapsed or refractory AML; 3) study 2215-CL-0301: a phase 3 open-label, multicentre, randomized study of ASP2215 versus salvage chemotherapy in patients with

Positive Opinion adopted by consensus on 05.05.2022.

---

relapsed or refractory AML with FMS-like tyrosine kinase 3 (FLT3) mutation.  
The RMP (version 2.0) is updated in order to address the missing information regarding the safety of Xospata (gilteritinib)."  
Opinion adopted on 05.05.2022.  
Request for Supplementary Information adopted on 10.02.2022.

---

**Zejula - niraparib -  
EMA/H/C/004249/II/0033, Orphan**  
GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang, PRAC Rapporteur: Jan Neuhauser, "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning and add MDS/AML to the list of adverse drug reactions (ADRs) with frequency common, and update of section 5.1 based on final results from NOVA study (213356); this is a Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer. In addition, the MAH took this opportunity to update section 4.4 and 4.6 to update information on contraception based on EMA and CTFG recommendations. The Package Leaflet is updated accordingly. The RMP version 6 has also been submitted."  
Request for Supplementary Information adopted on 19.05.2022, 10.02.2022.

Request for supplementary information adopted with a specific timetable.

See 9.1

---

**Zepatier - elbasvir / grazoprevir -  
EMA/H/C/004126/II/0034**  
Merck Sharp & Dohme B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, "Submission of the final report from study MK-5172-017, listed as a category 3 study in the RMP. This is a Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with Zepatier in a Prior Clinical Trial. The submission of the study report addresses MEA 002.1. The RMP version 5.1 has also been submitted."  
Opinion adopted on 05.05.2022.  
Request for Supplementary Information adopted on 07.04.2022.

Positive Opinion adopted by consensus on 05.05.2022.

#### **B.5.4. PRAC assessed procedures**

---

PRAC Led

**Adasuve - loxapine -  
EMA/H/C/002400/II/0033**

Ferrer Internacional s.a., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to update safety information on Bronchospasm based on final results from study AMDC-204-401 EU PASS (assessed in procedure EMA/H/C/0002400/II/0032): Post-authorisation Observational Study to Evaluate the Safety of ADASUVE (Staccato loxapine for inhalation) in Agitated Persons in Routine Clinical Care, a category 3 study in the RMP; the Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 05.05.2022, 02.12.2021.

Request for supplementary information adopted with a specific timetable.

---

PRAC Led

**Enbrel - etanercept -  
EMA/H/C/000262/II/0244**

Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "C.I.13: Submission of the final report from study B1801310 (BIKER), listed as a category 3 study in the RMP. This is an observational Post-Authorisation Safety Study (PASS) of Etanercept and Methotrexate in the treatment of Juvenile Idiopathic Arthritis (JIA) using data obtained from participants in the German Biologics JIA Registry (BIKER) to monitor long-term safety and effectiveness of etanercept in the treatment of JIA in regular clinical practice." Opinion adopted on 05.05.2022. Request for Supplementary Information adopted on 10.02.2022, 02.09.2021.

Positive Opinion adopted by consensus on 05.05.2022.

---

PRAC Led

**HEPLISAV B - hepatitis b surface antigen -  
EMA/H/C/005063/II/0014**

Dynavax GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus,

Positive Opinion adopted by consensus on 05.05.2022

---

---

"Submission of the final report from study (HBV25) listed as a category 3 PASS study in the RMP. This is a post-marketing observational surveillance study comparing the occurrence of Acute Myocardial Infarction (AMI) in recipients of HEPLISAV-B with recipients of another hepatitis B vaccine. As a consequence, the RMP version 1.2 has also been submitted, in which the MAH proposed the removal of AMI as an important potential risk from the list of safety concerns."

Opinion adopted on 05.05.2022.

---

PRAC Led

**Lemtrada - alemtuzumab -**

**EMA/H/C/003718/II/0041**

Sanofi Belgium, Duplicate, Duplicate of Lemtrada (WD), Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Submission of an updated RMP version 10.0 in order to include the new important identified risk "Autoimmune Encephalitis" and to introduce changes in accordance to the rapporteurs' requests received as part of procedure EMA/H/C/003718/II/0038."

Request for Supplementary Information adopted on 05.05.2022.

Request for supplementary information adopted with a specific timetable.

---

PRAC Led

**Otezla - apremilast -**

**EMA/H/C/003746/II/0038**

Amgen Europe B.V., Rapporteur: Peter Kiely, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "C.I.13 - Submission of the final study report (CSR) from PsOBest Registry, listed as a category 3 study in the RMP. This is an observational study to assess the long-term safety and effectiveness of apremilast in routine clinical practice in Germany.

The RMP version 14.0 has also been submitted."

Opinion adopted on 05.05.2022.

Request for Supplementary Information adopted on 30.09.2021.

Positive Opinion adopted by consensus on 05.05.2022.

---

PRAC Led

**Remicade - infliximab -**

**EMA/H/C/000240/II/0231**

Janssen Biologics B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga,

Positive Opinion adopted by consensus on 05.05.2022.

---

PRAC-CHMP liaison: Kristina Dunder,  
"Submission of the final report of the Remicade  
AntiRheumatic Therapy in Sweden (ARTIS)  
registry study. The ARTIS registry study was  
performed to fulfil a post-authorisation measure  
in the RMP for Remicade. The updated RMP  
v20.1. has also been submitted, including  
revisions agreed in previous procedures."  
Opinion adopted on 05.05.2022.  
Request for Supplementary Information adopted  
on 13.01.2022.

---

PRAC Led  
**Uptravi - selexipag -  
EMA/H/C/003774/II/0035**  
Janssen-Cilag International N.V., Rapporteur:  
Martina Weise, PRAC Rapporteur: Nathalie  
Gault, PRAC-CHMP liaison: Alexandre Moreau,  
"Submission of an updated RMP version 9.3 in  
order to include the amendment of the ongoing  
EXPOSURE study protocol, to add the EXTRACT  
study (67896049PAH0002) as an additional  
pharmacovigilance activity (PASS) and to  
include the update of the PRAC-approved  
EDUCATE PASS protocol (assessed in  
EMA/H/C/003774/MEA/003.4)."  
Request for Supplementary Information adopted  
on 05.05.2022.

Request for supplementary information adopted  
with a specific timetable.

---

PRAC Led  
**Vargatef - nintedanib -  
EMA/H/C/002569/II/0044**  
Boehringer Ingelheim International GmbH,  
Rapporteur: Thalia Marie Estrup Blicher, PRAC  
Rapporteur: Georgia Gkegka, PRAC-CHMP  
liaison: Konstantina Alexopoulou, "Submission  
of an updated RMP version 10.0 in order to  
remove safety concerns that were classified as  
important identified risks, important potential  
risks and missing information, based on  
cumulative post-marketing experience. The MAH  
is also proposing an update of the ATC code, an  
update of post-marketing exposure, the removal  
of adverse event follow-up forms and an update  
of search strategies."  
Request for Supplementary Information adopted  
on 05.05.2022, 10.02.2022.

Request for supplementary information adopted  
with a specific timetable.

---

PRAC Led  
**VPRIV - velaglucerase alfa -  
EMA/H/C/001249/II/0049, Orphan**  
Takeda Pharmaceuticals International AG,

Request for supplementary information adopted  
with a specific timetable.

---



---

Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of final physician data study results for PASS study "Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey among Health Care Professionals and Patient/Caregivers to Assess their Knowledge and Attitudes on Prescribing and Home Administration Conditions of Velaglucerase Alpha (VPRIV) in 6 European Countries" (EUPASS 14255)"

Request for Supplementary Information adopted on 05.05.2022, 02.12.2021, 08.07.2021, 11.02.2021, 26.11.2020.

---

PRAC Led

**Zessly - infliximab -**

**EMA/H/C/004647/II/0020**

Sandoz GmbH, Rapporteur: Eva Skovlund, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the updated RMP version 3.0 to remove the RABBIT registry as an additional pharmacovigilance activity in alignment with the updated version of the reference product Remicade RMP (v19) and to remove the BADBIR registry as an additional pharmacovigilance activity."

Opinion adopted on 05.05.2022.

Request for Supplementary Information adopted on 13.01.2022.

Positive Opinion adopted by consensus on 05.05.2022.

---

PRAC Led

**WS2151**

**Aflunov-**

**EMA/H/C/002094/WS2151/0071**

**Foclivia-**

**EMA/H/C/001208/WS2151/0068**

Seqirus S.r.l, Lead Rapporteur: Armando Genazzani, Lead PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, "Update of the RMP (part I, II, III, IV, V and VI) for AFLUNOV and FOCLIVIA in order to align the list of safety concerns for the products. The modules 'Epidemiology of the indication and target population' and 'Identified and potential risks' and the section of missing information are updated. Some potential risks have been reclassified following the definition as per GVP Module V rev.2. RMP version 4.0 was approved with this variation."

Opinion adopted on 05.05.2022.

Positive Opinion adopted by consensus on 05.05.2022.

---

Request for Supplementary Information adopted on 10.02.2022, 28.10.2021.

---

### **B.5.5. CHMP-CAT assessed procedures**

---

<b>Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0050, ATMP</b> Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo Opinion adopted on 19.05.2022, 13.05.2022.	Positive Opinion adopted by consensus on 19.05.2022.
---	--

---

<b>Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0052/G, ATMP</b> Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo Request for Supplementary Information adopted on 13.05.2022.	Request for supplementary information adopted with a specific timetable.
---	--

---

<b>Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0053, Orphan, ATMP</b> Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang, "Submission of the final report from study CCTL019H2301 (BELINDA) listed as an obligation in the Annex II of the Product Information. This is a randomized open-label parallel-group multicentre Phase III trial to evaluate the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory B-cell aggressive NHL after failure of rituximab and anthracycline containing first-line immune-chemotherapy. The Annex II is updated accordingly." Request for Supplementary Information adopted on 13.05.2022.	Request for supplementary information adopted with a specific timetable.
--	--

---

<b>Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0020/G, Orphan, ATMP</b> Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege Opinion adopted on 19.05.2022, 13.05.2022. Request for Supplementary Information adopted on 18.03.2022, 10.12.2021.	Positive Opinion adopted by consensus on 19.05.2022.
--	--

---

<b>Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0024, Orphan,</b>	Positive Opinion adopted by consensus on
--	--

---

<p><b>ATMP</b> Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege, Opinion adopted on 19.05.2022, 13.05.2022. Request for Supplementary Information adopted on 18.03.2022.</p>	<p>19.05.2022.</p>
<p><b>WS2247</b> <b>Tecartus-</b> <b>EMA/H/C/005102/WS2247/0020</b> <b>Yescarta-</b> <b>EMA/H/C/004480/WS2247/0050</b> Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Request for Supplementary Information adopted on 13.05.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

#### **B.5.6. CHMP-PRAC-CAT assessed procedures**

#### **B.5.7. PRAC assessed ATMP procedures**

<p>PRAC Led <b>Imlygic - talimogene laherparepvec -</b> <b>EMA/H/C/002771/II/0051, ATMP</b> Amgen Europe B.V., PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from study 20180062; "Observational Research Study Report (ORSR)" listed as a category 3 study in the RMP. This is a multinational, non-interventional, cross- sectional survey study for the patients aged ≥ 18 years who have received IMLYGIC at least once in the 3 months prior to completing the survey to evaluate the effectiveness of the patient-directed aRMMS. The primary objective of this study is to evaluate patients' knowledge levels of the key messages included in the IMLYGIC Patient Safety Brochure among patients who receive IMLYGIC." Request for Supplementary Information adopted on 13.05.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
---	---

#### **B.5.8. Unclassified procedures and worksharing procedures of type I variations**

<p><b>WS2136</b> <b>Esperoct-</b></p>	<p>Positive Opinion adopted by consensus on</p>
---	---

<p><b>EMA/H/C/004883/WS2136/0009</b>  <b>NovoEight-</b>  <b>EMA/H/C/002719/WS2136/0039</b>  Novo Nordisk A/S, Lead Rapporteur: Jan Mueller-Berghaus  Opinion adopted on 28.04.2022.  Request for Supplementary Information adopted on 03.02.2022.</p>	28.04.2022.
<p><b>WS2227</b>  <b>Esperoct-</b>  <b>EMA/H/C/004883/WS2227/0011</b>  <b>NovoEight-</b>  <b>EMA/H/C/002719/WS2227/0040</b>  Novo Nordisk A/S, Lead Rapporteur: Jan Mueller-Berghaus  Request for Supplementary Information adopted on 28.04.2022.</p>	Request for supplementary information adopted with a specific timetable.
<p><b>WS2229/G</b>  <b>Efficib-</b>  <b>EMA/H/C/000896/WS2229/0105/G</b>  <b>Janumet-</b>  <b>EMA/H/C/000861/WS2229/0104/G</b>  <b>Ristfor-</b>  <b>EMA/H/C/001235/WS2229/0092/G</b>  <b>Velmetia-</b>  <b>EMA/H/C/000862/WS2229/0108/G</b>  Merck Sharp &amp; Dohme B.V., Lead Rapporteur: Johann Lodewijk Hillege  Opinion adopted on 19.05.2022.</p>	Positive Opinion adopted by consensus on 19.05.2022.
<p><b>WS2239/G</b>  <b>Hexacima-</b>  <b>EMA/H/C/002702/WS2239/0128/G</b>  <b>Hexyon-</b>  <b>EMA/H/C/002796/WS2239/0132/G</b>  Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus  Request for Supplementary Information adopted on 12.05.2022.</p>	Request for supplementary information adopted with a specific timetable.
<p><b>WS2240</b>  <b>HyQvia-EMA/H/C/002491/WS2240/0077</b>  <b>Kiovig-EMA/H/C/000628/WS2240/0116</b>  Baxalta Innovations GmbH, Lead Rapporteur: Jan Mueller-Berghaus  Opinion adopted on 19.05.2022.</p>	Positive Opinion adopted by consensus on 19.05.2022.
<p><b>WS2273</b>  <b>Rixathon-</b>  <b>EMA/H/C/003903/WS2273/0055</b>  <b>Riximyo-</b></p>	Positive Opinion adopted by consensus on 19.05.2022.

---

**EMA/H/C/004729/WS2273/0056**

Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus, "To update section 6.6 of the SmPC and section 2 of the PL to align the wording with the originator Mabthera, following finalisation of procedure EMA/H/C/000165/II/0185/G.

In addition, the marketing authorisation holder has taken the opportunity to implement minor editorial changes in the PI."

Opinion adopted on 19.05.2022.

---

**B.5.9. Information on withdrawn type II variation / WS procedure**

---

**Ondexxya - andexanet alfa -  
EMA/H/C/004108/II/0027**

The MAH withdrew the procedure on 26.04.2022.

Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus

Request for Supplementary Information adopted on 17.03.2022.

Withdrawal request submitted on 26.04.2022.

---

**B.5.10. Information on type II variation / WS procedure with revised timetable****B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION****B.6.1. Start of procedure for New Applications: timetables for information**

---

**aflibercept - EMA/H/C/006022**

treatment of age-related macular degeneration (AMD) and visual impairment

---

**polihexanide - EMA/H/C/005858, Orphan**

SIFI SPA, For the treatment of acanthamoeba keratitis

---

**niraparib tosylate monohydrate /****abiraterone acetate - EMA/H/C/005932**

treatment of adult patients with prostate cancer

---

**sars-cov-2 virus, beta-propiolactone****inactivated - EMA/H/C/006019**

indicated for active immunization against coronavirus disease 2019 (COVID-19)

---

**ferumoxytol - EMA/H/C/005974**

intravenous treatment of iron deficiency anaemia (IDA)

---

---

**glofitamab - EMEA/H/C/005751, Orphan**  
Roche Registration GmbH, treatment of diffuse  
large B-cell lymphoma

---

**adagrasib - EMEA/H/C/006013**  
treatment of patients with advanced non-small  
cell lung cancer (NSCLC) with KRAS G12C  
mutation

---

**lacosamide - EMEA/H/C/006047**  
treatment of epilepsy

---

**futibatinib - EMEA/H/C/005627, Orphan**  
Taiho Pharma Netherlands B.V., treatment of  
cholangiocarcinoma

---

**mirikizumab - EMEA/H/C/005122**  
treatment of moderately to severely active  
ulcerative colitis

---

**sugammadex - EMEA/H/C/006046**  
reversal of neuromuscular blockade induced by  
rocuronium or vecuronium

---

**oteseconazole - EMEA/H/C/005682**  
treatment and prevention of recurrent  
vulvovaginal candidiasis (RVVC) including the  
acute episodes of RVVC in adult women

---

### **B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information**

---

**Spikevax - elasomeran -  
EMEA/H/C/005791/X/0064**  
Moderna Biotech Spain, S.L., Rapporteur: Jan  
Mueller-Berghaus, Co-Rapporteur: Andrea  
Laslop, "Extension application to add a new  
strength of 0.10 mg/ml in a 5-dose vial."

---

**Spikevax - elasomeran -  
EMEA/H/C/005791/X/0065**  
Moderna Biotech Spain, S.L., Rapporteur: Jan  
Mueller-Berghaus, Co-Rapporteur: Andrea  
Laslop, "Extension application to add a new  
strength of 0.10 mg/ml in pre-filled syringe."

---

### **B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information**

---

**in vitro diagnostic medical device -** See also 6.3  
**EMEA/H/D/006065**

---

---

In-vitro quantitative determination of anti-Müllerian hormone (AMH) in human serum and plasma  
Request for Supplementary Information adopted on 22.04.2022, 24.03.2022.

---

**sutimlimab - EMEA/H/C/005776, Orphan**  
Genzyme Europe BV, treatment of haemolysis in adult patients with cold agglutinin disease (CAD)  
List of Questions adopted on 24.02.2022.

---

**maralixibat - EMEA/H/C/005857, Orphan**  
Mirum Pharmaceuticals International B.V.,  
Treatment of cholestatic liver disease in patients with Alagille syndrome (ALGS) 1 year of age and older  
List of Questions adopted on 27.01.2022.

---

**tirzepatide - EMEA/H/C/005620**  
treatment of adults with type 2 diabetes mellitus  
List of Questions adopted on 24.02.2022.

---

**iodine (131I) omburtamab - EMEA/H/C/005499, Orphan**  
Y-Mabs Therapeutics A/S, treatment of neuroblastoma  
List of Questions adopted on 16.09.2021.

---

**in vitro diagnostic medical device - EMEA/H/D/006078** See also 6.3  
detection of PD-L1 protein  
Request for Supplementary Information adopted on 22.04.2022.

---

**teriflunomide - EMEA/H/C/005962**  
treatment of multiple sclerosis (MS)  
List of Questions adopted on 27.01.2022.

---

**teriparatide - EMEA/H/C/005793**  
treatment of osteoporosis  
List of Questions adopted on 20.05.2021.

---

**ranibizumab - EMEA/H/C/005617**  
treatment of neovascular age-related macular degeneration (AMD)  
List of Questions adopted on 27.01.2022.

---

#### **B.6.4. Annual Re-assessments: timetables for adoption**

---

**Chenodeoxycholic acid Leadiant - chenodeoxycholic acid -**

---

---

**EMA/H/C/004061/S/0020, Orphan**

Leadiant GmbH, Rapporteur: Anastasia

Mountaki, PRAC Rapporteur: Adam

Przybylkowski

---

**DECTOVA - zanamivir -****EMA/H/C/004102/S/0013**

GlaxoSmithKline Trading Services Limited,

Rapporteur: Ingrid Wang, PRAC Rapporteur:

Ulla Wändel Liminga

---

**Elaprase - idursulfase -****EMA/H/C/000700/S/0099**

Takeda Pharmaceuticals International AG

Ireland Branch, Rapporteur: Johann Lodewijk

Hillege, PRAC Rapporteur: Liana Gross-

Martirosyan

---

**Evoltra - clofarabine -****EMA/H/C/000613/S/0076**

Genzyme Europe BV, Rapporteur: Alexandre

Moreau, PRAC Rapporteur: Tiphaine Vaillant

---

**Firdapse - amifampridine -****EMA/H/C/001032/S/0073**

SERB SA, Rapporteur: Kristina Dunder, PRAC

Rapporteur: Ulla Wändel Liminga

---

**B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed**

---

**Adakveo - crizanlizumab -****EMA/H/C/004874/R/0008, Orphan**

Novartis Europharm Limited, Rapporteur:

Daniela Philadelphia, PRAC Rapporteur: Jean-

Michel Dogné

---

**ADYNOVI - ruriococog alfa pegol -****EMA/H/C/004195/R/0033**

Baxalta Innovations GmbH, Rapporteur: Andrea

Laslop, Co-Rapporteur: Kristina Dunder, PRAC

Rapporteur: Menno van der Elst

---

**Alkindi - hydrocortisone -****EMA/H/C/004416/R/0014**

Diurnal Europe BV, Rapporteur: Karin Janssen

van Doorn, PRAC Rapporteur: Annika Folin

---

**Fasenra - benralizumab -****EMA/H/C/004433/R/0044**

AstraZeneca AB, Rapporteur: Fátima Ventura,

Co-Rapporteur: Thalia Marie Estrup Blicher,

---



---

PRAC Rapporteur: David Olsen

---

**Hemlibra - emicizumab -  
EMA/H/C/004406/R/0032**

Roche Registration GmbH, Rapporteur:  
Alexandre Moreau, Co-Rapporteur: Jan Mueller-  
Berghaus, PRAC Rapporteur: Amelia Cupelli

---

**Intrarosa - prasterone -  
EMA/H/C/004138/R/0022**

Endoceutics S.A., Rapporteur: Jean-Michel Race,  
Co-Rapporteur: Jayne Crowe, PRAC Rapporteur:  
Menno van der Elst

---

**Jorveza - budesonide -  
EMA/H/C/004655/R/0016, Orphan**

Dr. Falk Pharma GmbH, Rapporteur: Martina  
Weise, Co-Rapporteur: Tomas Radimersky,  
PRAC Rapporteur: Zane Neikena

---

**MVASI - bevacizumab -  
EMA/H/C/004728/R/0025**

Amgen Technology (Ireland) Unlimited  
Company, Duplicate, Duplicate of KYOMARC,  
Rapporteur: Eva Skovlund, Co-Rapporteur: Jan  
Mueller-Berghaus, PRAC Rapporteur: Anette  
Kirstine Stark

---

**Ocrevus - ocrelizumab -  
EMA/H/C/004043/R/0033**

Roche Registration GmbH, Rapporteur: Thalia  
Marie Estrup Blicher, Co-Rapporteur: Armando  
Genazzani, PRAC Rapporteur: Brigitte Keller-  
Stanislawski

---

**Ozempic - semaglutide -  
EMA/H/C/004174/R/0030**

Novo Nordisk A/S, Rapporteur: Johann Lodewijk  
Hillege, Co-Rapporteur: Ebru Karakoc Madsen,  
PRAC Rapporteur: Annika Folin

---

## **B.6.6. VARIATIONS – START OF THE PROCEDURE**

**Timetables for adoption** provided that the validation has been completed.

## **B.6.7. Type II Variations scope of the Variations: Extension of indication**

---

**Ceprothin - human protein C -  
EMA/H/C/000334/II/0127**

Takeda Manufacturing Austria AG, Rapporteur:  
Jan Mueller-Berghaus, Co-Rapporteur: Armando  
Genazzani, PRAC Rapporteur: Brigitte Keller-

---

---

Stanislawski, "Extension of indication to include long-term prophylaxis (deletion of wording 'short-term' and currently listed conditions) of purpura fulminans and coumarin induced skin necrosis in patients with severe congenital protein C deficiency, based on a re-analysis of long-term prophylaxis data from the pivotal study 400101; a phase 2/3 clinical study undertaken to evaluate PK, safety and efficacy of CEPROTIN in patients with severe congenital PC deficiency for the treatment of acute thrombotic episodes, for short-term thromboembolic prophylaxis and for long-term prophylactic treatment. As a consequence, sections 4.1, 4.2 and 4.4 of the SmPC are updated and the Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. Version 2.0 of the RMP has also been submitted. In addition, MAH took the opportunity to correct the address of the manufacturer of the biological active substance in Annex II following variation EMEA/H/C/000334/IAIN/0126/G."

---

**Dupixent - dupilumab -**

**EMEA/H/C/004390/II/0062**

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Kimmo Jaakkola, "Extension of indication to include treatment of eosinophilic esophagitis (EoE) in adults and adolescents 12 years and older who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy, based on the pivotal study R668-EE-1774. This is an ongoing phase 3, randomized, double-blind, placebo-controlled, 3-part (A, B, C) safety and efficacy study with an initial 24-week treatment period in adults ( $\geq 18$  years of age) and adolescents ( $\geq 12$  to  $< 18$  years of age) with EoE, and which includes an extended treatment period to a total of 52 weeks. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted."

---

**Dupixent - dupilumab -**

**EMEA/H/C/004390/II/0063**

---

---

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Kimmo Jaakkola, "Extension of indication to include treatment of adults with moderate to severe prurigo nodularis (PN) who are candidates for systemic therapy, based on results from studies EFC16459 and EFC16460 (PRIME and PRIME2); these are two phase 3, 24-week, randomized, double-blind, placebo-controlled, multi-centre, parallel group studies undertaken to evaluate the efficacy and safety of dupilumab in patients 18 years of age and older with moderate to severe PN, who are inadequately controlled on topical prescription therapies or when those therapies are not advisable. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. As part of this application, the MAH is also requesting a 1-year extension of the market protection."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

---

**Imfinzi - durvalumab -  
EMA/H/C/004771/II/0045**

AstraZeneca AB, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: David Olsen, "Extension of indication to include Imfinzi in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC), based on final results from study D419CC00002 (HIMALAYA); This was a randomized, open-label, multi-centre phase III study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. Version 6.1 of the RMP has also been submitted."

---

**Imfinzi - durvalumab -  
EMA/H/C/004771/II/0046**

AstraZeneca AB, Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Blanca Garcia-

---

---

Ochoa, PRAC Rapporteur: David Olsen, "Extension of indication to include Imfinzi in combination with chemotherapy for the treatment of adults with locally advanced or metastatic biliary tract cancer (BTC), based on the second interim analysis from the ongoing pivotal study D933AC00001 (TOPAZ-1); a phase III randomized, double-blind, placebo-controlled, multi-regional, international study conducted to assess the efficacy and safety of durvalumab in combination with the current standard of care Gemcitabine/Cisplatin for the first-line treatment of patients with locally advanced or metastatic BTC. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated and the Package leaflet has been updated accordingly. Version 7.1 of the RMP has also been submitted. "

---

**Keytruda - pembrolizumab -  
EMA/H/C/003820/II/0121**

Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst, "Extension of indication to include Keytruda as monotherapy for the adjuvant treatment of adults with stage IB (T2a  $\geq$  4 cm), II or IIIA non-small cell lung carcinoma (NSCLC) who have undergone complete resection, based on study KEYNOTE-091; an ongoing Phase 3, randomized, triple-blinded, placebo-controlled, multicentre study of pembrolizumab versus placebo in patients with early-stage NSCLC after resection and completion of standard adjuvant therapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are being updated and the Package Leaflet is updated in accordance. An updated RMP version 39.1 was also submitted."

---

**Retsevmo - selpercatinib -  
EMA/H/C/005375/II/0014/G**

Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst, "Extension of indication to include first-line treatment of advanced RET-mutant medullary thyroid cancer (MTC) in adults and adolescents 12 years and older based on interim results from study LIBRETTO-001 (LOXO-RET-17001) on the clinical safety and efficacy of selpercatinib in patients with RET-mutant MTC who are cabozantinib and vandetanib

---

---

treatment-naïve (MTC:-Cab/-Van). LIBRETTO-001 is a global, multicohort, open-label, Phase 1/2 study in adult and adolescent patients with advanced RET-altered tumours. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted.

As part of the application the MAH is requesting a 1-year extension of the market protection. The application also includes an updated Phase II Environmental Risk Assessment in order to reflect the patient population as per the approved indication.”

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

---

**Trecondi - treosulfan -  
EMA/H/C/004751/II/0014, Orphan**

medac Gesellschaft für klinische Spezialpräparate mbH, Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos, “Extension of indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population) for Trecondi 1 g/5 g powder for solution for infusion based on final 12-months follow-up results of study MC-FludT.16/NM; a randomised phase II interventional study aimed to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non-malignant diseases. Further, the MAH proposes to amend an existing warning on skin toxicity based on new literature data. Moreover, the MAH proposes to introduce a slightly modified dosing regimen according to the patient’s body surface based on long-term follow-up data of paediatric study MC-FludT.17/M, a Phase II trial to describe the safety and efficacy of Treosulfan based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies, as well as a final analysis of the population pharmacokinetics of treosulfan in paediatric patients. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.0 of the RMP has also

---

---

been submitted.”

---

#### **B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects**

---

**ADCETRIS - brentuximab vedotin -  
EMA/H/C/002455/II/0102/G, Orphan**

Takeda Pharma A/S, Rapporteur: Paula  
Boudewina van Hennik

---

**Benepali - etanercept -  
EMA/H/C/004007/II/0065/G**

Samsung Bioepis NL B.V., Rapporteur: Andrea  
Laslop

---

**Edarbi - azilsartan medoxomil -  
EMA/H/C/002293/II/0031**

Takeda Pharma A/S, Rapporteur: Johann  
Lodewijk Hillege

---

**Ervebo - recombinant vesicular stomatitis  
virus - Zaire ebolavirus vaccine (live) -  
EMA/H/C/004554/II/0022/G**

Merck Sharp & Dohme B.V., Rapporteur:  
Christophe Focke

---

**Hepcludex - bulevirtide -  
EMA/H/C/004854/II/0014/G, Orphan**

Gilead Sciences Ireland Unlimited Company,  
Rapporteur: Filip Josephson

---

**LIVOGIVA - teriparatide -  
EMA/H/C/005087/II/0010**

Theramex Ireland Limited, Rapporteur: Daniela  
Philadelphly

---

**Mosquirix - plasmodium falciparum and  
hepatitis B vaccine (recombinant,  
adjuvanted) -**

**EMA/H/W/002300/II/0061/G**

GlaxoSmithkline Biologicals SA, Rapporteur: Jan  
Mueller-Berghaus

---

**Nuceiva - botulinum toxin type A -  
EMA/H/C/004587/II/0025/G**

Evolus Pharma B.V., Rapporteur: Peter Kiely

---

**Pemetrexed Accord - pemetrexed -  
EMA/H/C/004072/II/0020**

Accord Healthcare S.L.U., Generic, Generic of  
Alimta, Rapporteur: John Joseph Borg

---

**Plegridy - peginterferon beta-1a -  
EMA/H/C/002827/II/0067**

---

---

Biogen Netherlands B.V., Rapporteur: Johann  
Lodewijk Hillege

---

**Polivy - polatuzumab vedotin -**  
**EMA/H/C/004870/II/0017/G, Orphan**  
Roche Registration GmbH, Rapporteur:  
Alexandre Moreau

---

**Privigen - human normal immunoglobulin -**  
**EMA/H/C/000831/II/0188**  
CSL Behring GmbH, Rapporteur: Jan Mueller-  
Berghaus

---

**Puregon - follitropin beta -**  
**EMA/H/C/000086/II/0124**  
Organon N.V., Rapporteur: Peter Kiely

---

**Pyramax - pyronaridine / artesunate -**  
**EMA/H/W/002319/II/0031/G**  
Shin Poong Pharmaceutical Co., Ltd.,  
Rapporteur: Jean-Michel Race

---

**SARCLISA - isatuximab -**  
**EMA/H/C/004977/II/0015**  
sanofi-aventis groupe, Rapporteur: Paula  
Boudewina van Hennik

---

**Simulect - basiliximab -**  
**EMA/H/C/000207/II/0114/G**  
Novartis Europharm Limited, Rapporteur: Jan  
Mueller-Berghaus

---

**Spectrila - asparaginase -**  
**EMA/H/C/002661/II/0031**  
medac Gesellschaft für klinische  
Spezialpräparate mbH, Rapporteur: Andrea  
Laslop

---

**Stelara - ustekinumab -**  
**EMA/H/C/000958/II/0094/G**  
Janssen-Cilag International N.V., Rapporteur:  
Jayne Crowe

---

**Trulicity - dulaglutide -**  
**EMA/H/C/002825/II/0064/G**  
Eli Lilly Nederland B.V., Rapporteur: Martina  
Weise

---

**Vimizim - elosulfase alfa -**  
**EMA/H/C/002779/II/0037/G, Orphan**  
BioMarin International Limited, Rapporteur:  
Johann Lodewijk Hillege

---

**WS2258/G**  
**Infanrix hexa-**  
**EMA/H/C/000296/WS2258/0315/G**

---

---

GlaxoSmithkline Biologicals SA, Lead  
Rapporteur: Christophe Focke

---

**WS2264**

**Humalog-**

**EMA/H/C/000088/WS2264/0194**

**Liprolog-**

**EMA/H/C/000393/WS2264/0154**

Eli Lilly Nederland B.V., Lead Rapporteur:  
Kristina Dunder

---

**WS2275/G**

**GONAL-f-**

**EMA/H/C/000071/WS2275/0156/G**

**Pergoveris-**

**EMA/H/C/000714/WS2275/0078/G**

Merck Europe B.V., Lead Rapporteur: Thalia  
Marie Estrup Blicher

---

**WS2285/G**

**Humalog-**

**EMA/H/C/000088/WS2285/0195/G**

**Liprolog-**

**EMA/H/C/000393/WS2285/0155/G**

Eli Lilly Nederland B.V., Lead Rapporteur:  
Kristina Dunder

---

### **B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects**

---

**Besremi - ropeginterferon alfa-2b -**

**EMA/H/C/004128/II/0021**

AOP Orphan Pharmaceuticals GmbH,  
Rapporteur: Janet Koenig, "Update of sections  
4.8, 5.1 and 5.2 of the SmPC based on results  
from CONTINUATION-PV study. An open-label,  
multicentre, phase IIIb study assessing the  
long-term efficacy and safety of AOP2014 and  
standard first-line treatment (BAT) in patients  
with polycythaemia vera who previously  
participated in the PROUDPV study. The Package  
Leaflet is updated accordingly."

---

**Bydureon - exenatide -**

**EMA/H/C/002020/II/0074**

AstraZeneca AB, Rapporteur: Kristina Dunder,  
"Update of section 4.8 of the SmPC in order to  
add cholelithiasis and cholecystitis to the list of  
adverse drug reactions (ADRs) with frequency  
(unknown) based on the cumulative review of  
pre-clinical and clinical study data, post-  
marketing data, medical/scientific literature and

---



---

signal searches in internal and external databases on 'Gallbladder-related disorders' and exenatide.

The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC."

---

**BYETTA - exenatide -  
EMA/H/C/000698/II/0078**

AstraZeneca AB, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add cholelithiasis and cholecystitis to the list of adverse drug reactions (ADRs) with frequency (unknown) based on the cumulative review of pre-clinical and clinical study data, post-marketing data, medical/scientific literature and signal searches in internal and external databases on 'Gallbladder-related disorders' and exenatide.

The Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

---

**Evrenzo - roxadustat -  
EMA/H/C/004871/II/0002**

Astellas Pharma Europe B.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add dermatitis exfoliative generalised (DEG) to the list of adverse drug reactions (ADRs) with frequency unknown based on post-marketing data and literature. In addition, the MAH took the opportunity to amend the Annex IIB in order to reflect the fact that restricted prescription applies. Furthermore, the MAH took the opportunity to implement editorial changes to the SmPC."

---

**Eylea - aflibercept -  
EMA/H/C/002392/II/0080**

Bayer AG, Rapporteur: Alexandre Moreau, "Update of sections 4.2 and 5.1 of the SmPC in order to allow the individualisation of the treatment posology for intravitreal aflibercept in diabetic macular oedema (DME) indication based on a propensity-score-matching (PSM) analyses on patient-level-data comparison of the two pivotal studies in DME (VIVID & VISTA) versus the independently conducted Protocol T study as well as supporting data from a systematic literature review and confirmatory

---

---

data from the recently completed VIOLET Phase 3b study. The Package Leaflet is updated accordingly.”

---

**Fexinidazole Winthrop - fexinidazole -  
EMA/H/W/002320/II/0010**

sanofi-aventis groupe, Rapporteur: Fátima Ventura, “Update of section 4.4 of the SmPC in order to add a new warning on severe irreversible hepatotoxicity in patients with Cockayne syndrome based on case reports and literature reviews; the Package Leaflet is updated accordingly.”

---

**Imbruvica - ibrutinib -  
EMA/H/C/003791/II/0074**

Janssen-Cilag International N.V., Rapporteur: Filip Josephson, “Update of section 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the information related to Paediatrics following assessment done in procedure P46/035, based on results from the paediatric study LYM3003 “A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Paediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma”. The Package Leaflet is updated accordingly.”

---

**JCOVDEN - adenovirus type 26 encoding  
the SARS-CoV-2 spike glycoprotein -  
EMA/H/C/005737/II/0047/G**

Janssen-Cilag International N.V., Rapporteur: Christophe Focke, “Submission of the final reports from the non-clinical studies TV-TEC-207316, TV-TEC-207437, TOX15155, TV-TEC-215524 and TOX15252, listed as category 3 in the RMP. These are non-clinical studies conducted to further characterise the potential mechanisms underlying the important identified risks of thrombosis with thrombocytopenia syndrome (TTS) and thrombocytopenia, including immune thrombocytopenia (ITP).”

---

**Onpattro - patisiran -  
EMA/H/C/004699/II/0025, Orphan**

Alnylam Netherlands B.V., Rapporteur: Kristina Dunder, “Update of sections 4.2 and 5.1 of the SmPC based on interim results from study ALN-TTR02-006 listed as a category 3 study in the RMP; this is a multicentre, open-label, extension study to evaluate the long-term safety and efficacy of patisiran in patients with familial

---

---

amyloidotic polyneuropathy who have completed a prior clinical study with patisiran. In addition, the MAH took the opportunity to update section 3 of the SmPC .”

---

**Paxlovid - nirmatrelvir / ritonavir -  
EMA/H/C/005973/II/0009**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, “Update of sections 4.3 and 4.5 of the SmPC in order to remove piroxicam as a contraindicated medicinal product based on scientific literature. The package leaflet is updated accordingly.”

---

**Paxlovid - nirmatrelvir / ritonavir -  
EMA/H/C/005973/II/0010/G**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, “Update of section 4.8 of the SmPC to add hypersensitivity to the list of adverse drug reactions with frequency common, based on a cumulative search of the MAH safety database; the Package Leaflet is updated accordingly. Update of section 4.5 of the SmPC in order to add drug-drug interaction information with dabigatran (P-gp substrate) based on the clinical study results from study C4671012, a pharmacokinetic study to estimate the effect of Paxlovid on the pharmacokinetics of dabigatran; the Package Leaflet is updated accordingly. Update of section 4.5 of the SmPC in order to update the drug-drug interaction information of midazolam based on the clinical study results from study C4671013, a pharmacokinetic study to estimate the effect of Paxlovid on the pharmacokinetics of midazolam. The MAH is taking the opportunity to include editorial updates in sections 4.3 and 6.1 of the SmPC.”

---

**Paxlovid - nirmatrelvir / ritonavir -  
EMA/H/C/005973/II/0012/G**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, “Submission of the whole body autoradiographic study report in rats with PF-07321332 (alone) in order to fulfil LEG/002 and the final study report for the pre- and postnatal development (21GR149) in order to fulfil LEG/004; this is an oral (gavage) study of the effects of PF-07321332 on pre- and postnatal development, including maternal function in rats.”

---

---

**Pegasys - peginterferon alfa-2a -  
EMA/H/C/000395/II/0112**

Zr Pharma& GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 4.8 of the SmPC in order to include information on post-treatment recovery in growth based on final results from study YV25718 listed as a category 3 study in the RMP; this is a Phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO0258310) compared to untreated control in children with HBeAg-Positive Chronic Hepatitis B in the immune active phase.

The RMP version 9.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the Package Leaflet."

---

**Rybelsus - semaglutide -  
EMA/H/C/004953/II/0025**

Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add 'Hypersensitivity' to the list of adverse drug reactions (ADRs) with frequency uncommon; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

---

**Ryeqo - relugolix / estradiol /  
norethisterone acetate -  
EMA/H/C/005267/II/0009**

Gedeon Richter Plc., Rapporteur: Paula Boudewina van Hennik, "Update of sections 5.3 and 6.6 of the SmPC based on final results from MVT-601-9030\_Relugolix\_ZEOGRT\_Study (Rec); this is a fish, full life cycle test performed in the context of the Environmental Risk Assessment of relugolix. The Package Leaflet is updated accordingly."

---

**Shingrix - herpes zoster vaccine  
(recombinant, adjuvanted) -  
EMA/H/C/004336/II/0054**

GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, "Update of section 4.5 of the SmPC based on final results from study ZOSTER-059; this is a Phase IIIB, open label, randomised, controlled study to evaluate the immunogenicity, safety and reactogenicity of Shingrix when co-administered with Prevenar 13

---

in adults  $\geq$  50 years of age.

In addition, the MAH took the opportunity to update section 4.5 of the SmPC to update the existing statement to specify the incidence percentages of fever and shivering upon co-administration of Shingrix with PPV23 based on study ZOSTER-035.”

---

**SonoVue - sulphur hexafluoride -  
EMA/H/C/000303/II/0049**

Bracco International B.V., Rapporteur: Alexandre Moreau, “Update of sections 4.1, 4.4 and 5.1 of the SmPC based on final results from study BR1-145 listed as a PAES in the Annex II; this is an observational, retrospective, multicentre, comparative study conducted in patients below 18 years of age who had undergone a VUS exam with intravesically administered SonoVue/Lumason or a VCUG exam as part of their standard of care for evaluation of known or suspected VUR.”

---

**TAGRISO - osimertinib -  
EMA/H/C/004124/II/0047**

AstraZeneca AB, Rapporteur: Blanca Garcia-Ochoa, “Update of section 5.2 of the SmPC based on final results from studies ODIN-BM and ODIN-HV; these are two phase I clinical pharmacology studies conducted in EGFRm+ NSCLC patients (ODIN-BM) and healthy volunteers (ODIN-HV) to determine osimertinib blood-brain barrier (BBB) penetration and brain distribution in patients with brain metastases and healthy volunteers with an intact BBB, respectively.”

---

**TECFIDERA - dimethyl fumarate -  
EMA/H/C/002601/II/0078**

Biogen Netherlands B.V., Rapporteur: Martina Weise, “Submission of the final report from study 109MS408; upon request by the PRAC as per final PSUR assessment report of procedure EMA/H/C/PSUSA/00010143/20213. This is a Multicentre, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis Disease Activity and Patient-Reported Outcomes in Subjects with Relapsing Remitting Multiple Sclerosis in the Real-World Setting (PROTEC).”

---

**Trecondi - treosulfan -  
EMA/H/C/004751/II/0016, Orphan**

---

---

medac Gesellschaft für klinische Spezialpräparate mbH, Rapporteur: Fátima Ventura, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study MC-FludT.14/L Trial II; a phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens. The Package Leaflet is updated accordingly."

---

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -**

**EMA/H/C/005675/II/0074**

AstraZeneca AB, Rapporteur: Sol Ruiz, "Type II C.I.11.b, To update Annex IIE to remove the specific obligation relating to provision of process validation data for the active substance and finished product (SO1) which has been fulfilled, and to change the date of the specific obligation relating to the provision of additional information on stability of the active substance and finished product (and review the finished product specifications following further manufacturing experience) from June 2022 to January 2023 (SO2)."

---

**Veklury - remdesivir -**

**EMA/H/C/005622/II/0037/G**

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Grouped variations to update sections 4.5, 5.2 and 6.6 of the SmPC to update prescribing information related to interactions with other medicinal products, effect of intrinsic factors and COVID-19 disease on the pharmacokinetics (PK) of Veklury and its metabolites in the adult population. Data from the Phase 1 drug-drug interaction (DDI) study GS US 540 9013, adult COVID-19 participant PK data collected across two Phase 3 studies (GS-US-540-9012 and CO-US-540-5844), and an exposure-safety analysis are included in addition to nonclinical in vitro drug metabolism studies to complete the metabolism profiling. This variation is submitted to cover Recommendations 9, 11, 12 and 13 listed at the time of the conditional marketing authorisation (EMA/H/C/005622/0000) for Veklury. Package

---

---

Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce some linguistic amendments.”

---

**WS2249**

**Delstrigo-**

**EMA/H/C/004746/WS2249/0029**

**Pifeltro-EMA/H/C/004747/WS2249/0022**

Merck Sharp & Dohme B.V., Lead Rapporteur: Filip Josephson, “Update of section 5.1 of SmPC based on 2 non-clinical studies (Assessment of in vitro antiviral activity against HIV-1 Resistant mutant, Y318F, alone and in combination with 12 other Nnrti mutants; In vitro antiviral activity of doravirine (MK-1439) Against a panel of viruses bearing NNRTI resistance-associated Mutations).

In addition, the MAH took the opportunity to implement editorial changes in the SmPC and to update the list of local representatives in the Package Leaflet.”

---

**B.6.10. CHMP-PRAC assessed procedures**

---

**HyQvia - human normal immunoglobulin -**

**EMA/H/C/002491/II/0078**

Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, “Update of sections 4.8 and 5.1 of the SmPC in order to update safety data in paediatric population based on final results from study 161504 – Post-Authorisation Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Paediatric Subjects With Primary Immunodeficiency Diseases, listed as a category 3 study in the RMP. This is a paediatric interventional Phase 4 study performed to acquire additional data on safety, tolerability and immunogenicity of HyQvia in paediatric (age two to <18 years) patients with Primary Immunodeficiency Diseases (PID).

In addition, the MAH is taking this opportunity to update Annex II-D of the PI following procedure EMA/H/C/002491/II/0070/G. The RMP version 13.1 has also been submitted.”

---

**Kadcyla - trastuzumab emtansine -**

**EMA/H/C/002389/II/0064**

Roche Registration GmbH, Rapporteur: Thalia

---

---

Marie Estrup Blicher, PRAC Rapporteur: Anette Kirstine Stark, "Submission of the final report from study BO28407 (KAITLIN): A randomized, multicentre, open-label, Phase III trial comparing trastuzumab plus pertuzumab plus a taxane following anthracyclines versus trastuzumab emtansine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer listed as a category 3 study in the RMP.

The RMP version 15.0 has also been submitted."

---

**Ontozry - cenobamate -  
EMA/H/C/005377/II/0009**

Angelini S.p.A., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Jean-Michel Dogné, "Update of section 5.3 of the SmPC in order to update information on toxicity to reproduction and development based on final results from nonclinical study "Effects of Cenobamate (YKP3089) on Embryo-Fetal Development in Rats after Twice Daily Oral Administration". The RMP version 3.0 has also been submitted."

---

**Spikevax - elasomeran -  
EMA/H/C/005791/II/0062**

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "Submission of an updated RMP version 4.0 in order to remove 'anaphylaxis' as an important identified risk; to remove 'interaction with other vaccines' as a safety concern in study mRNA-1273-P904 following the outcome of the EMA/H/C/005791/MEA/004.4 procedure; to implement the WHO-approved INN 'elasomeran'; to update the study milestones for the mRNA-1273-P301, mRNA1273-P203, mRNA-1273-P201, mRNA-1273-P901, mRNA-1273-P903 and mRNA-1273-P910 studies and to add study mRNA-1273-P911 to the RMP. The Annex II of the Product Information is updated accordingly."

---

**Trecondi - treosulfan -  
EMA/H/C/004751/II/0012, Orphan**

medac Gesellschaft für klinische Spezialpräparate mbH, Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos, "Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with



---

regards to CYP3A4, CYP2C19 and P-gp including physiologically based pharmacokinetic (PBPK) modelling. Version 1.0 of the RMP has also been submitted.”

---

**Trecondi - treosulfan -**

**EMA/H/C/004751/II/0013, Orphan**

medac Gesellschaft für klinische Spezialpräparate mbH, Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos, “Update of section 5.3 of the SmPC in order to update the description of non-clinical information regarding musculoskeletal and connective tissue disorders in form of lympho-histiocytic infiltration in the skeletal muscles and renal and urinary disorders which show up as haematuria. These new determinations are based on results from study LPT 37259. A revised RMP version 1.0 was also submitted.”

---

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -**

**EMA/H/C/005675/II/0075**

AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, “Update of section 5.1 of the SmPC in order to include updated efficacy information based on the 6 months follow-up analysis from study D8110C00001 listed as a specific obligation in the Annex II; this is a phase III randomised, double-blind, placebo-controlled, multicentre study in adults to determine the safety, efficacy and immunogenicity of Vaxzevria. The RMP version 5.1 has also been submitted. The MAH removed the important identified risk of anaphylaxis from the list of safety concerns, updated the routine and additional pharmacovigilance activities section and took the opportunity to implement other administrative updates.”

---

**WS2274**

**Relvar Ellipta-**

**EMA/H/C/002673/WS2274/0054**

**Revinty Ellipta-**

**EMA/H/C/002745/WS2274/0052**

GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Maria del Pilar Rayon, “Submission of the final report from study HZA114971 listed as a category 3 study in the RMP. This is a multicentre randomised, double-

---

---

blind, placebo-controlled, parallel-group study to evaluate the effects of a one-year regimen of orally inhaled fluticasone furoate 50 mcg once daily on growth velocity in prepubertal, paediatric subjects with asthma. The RMP version 11.1 has also been submitted.”

---

#### **B.6.11. PRAC assessed procedures**

---

PRAC Led

**Brintellix - vortioxetine -  
EMA/H/C/002717/II/0037**

H. Lundbeck A/S, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, “Submission of the final report from study PASS 16034N listed as a category 3 study in the RMP. This is a non-interventional post-authorisation safety study (PASS) of vortioxetine in Europe - An analysis of European automated healthcare databases. The RMP version 4.0 has also been submitted.”

---

PRAC Led

**Duavive - estrogens conjugated /  
bazedoxifene -  
EMA/H/C/002314/II/0032**

Pfizer Europe MA EEIG, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, “Submission of an updated RMP version 3.2 in order to reflect the updated study milestones and completion of the post-authorisation safety study of CE/BZA in the United States (US PASS, Study B2311060) previously assessed as part of II/0030 (MEA002.15), as well as to update the post-marketing data with the data lock point of 31 October 2021.”

---

PRAC Led

**JCOVDEN - adenovirus type 26 encoding  
the SARS-CoV-2 spike glycoprotein -  
EMA/H/C/005737/II/0048/G**

Janssen-Cilag International N.V., PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, “Submission of the final reports from four exploratory studies conducted to further characterise the potential mechanisms underlying the important identified risk of thrombosis with thrombocytopenia syndrome (TTS). These studies evaluated the

---

---

levels of anti-PF4 antibodies using clinical samples, both from Ad26.COVID.S and other non-COVID-19 Ad26-based vaccine clinical studies. Interim results from an additional exploratory study are provided and the submission milestone for the final results has been updated. The RMP version 4.1 has been submitted and updated in line with this procedure and the ongoing procedure EMEA/H/C/005737/II/0047/G. In addition, the MAH removed the important identified risk of anaphylaxis from the list of safety concerns (PSUSA/00010916/202108), updated the routine pharmacovigilance activities section and took the opportunity to implement other administrative updates in the RMP in alignment with procedure EMEA/H/C/005737/II/033. "

---

PRAC Led

**WS2261**

**Lyrica-EMEA/H/C/000546/WS2261/0118**

**Pregabalin Pfizer-**

**EMEA/H/C/003880/WS2261/0047**

Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "To update SmPC sections 4.4 and 4.8 with a warning regarding severe cutaneous adverse reactions (SJS and TEN); the PL was updated accordingly."

---

PRAC Led

**WS2268**

**Dovato-EMEA/H/C/004909/WS2268/0031**

**Juluca-EMEA/H/C/004427/WS2268/0044**

**Tivicay-EMEA/H/C/002753/WS2268/0079**

**Triumeq-**

**EMEA/H/C/002754/WS2268/0104**

ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "To update section 4.8 of the SmPC and section 4 of the PL to include the ADR "weight increased" with a frequency "common". In addition, the marketing authorisation holder has taken the opportunity to implement a minor editorial change in the German SmPC for Juluca."

---

## **B.6.12. CHMP-CAT assessed procedures**

---

### **Kymriah - tisagenlecleucel - EMA/H/C/004090/II/0055, Orphan, ATMP**

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang

---

### **Kymriah - tisagenlecleucel - EMA/H/C/004090/II/0056, Orphan, ATMP**

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang, "Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy and safety information in paediatric population based on study CCTL019C2202, a phase II, single arm, multicentre open label trial to determine the safety and efficacy of tisagenlecleucel in paediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA).  
The Package Leaflet is updated accordingly."

---

### **WS2269**

#### **Tecartus-**

**EMA/H/C/005102/WS2269/0022**

#### **Yescarta-**

**EMA/H/C/004480/WS2269/0051**

Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

---

## **B.6.13. CHMP-PRAC-CAT assessed procedures**

---

### **Tecartus - brexucabtagene autoleucel - EMA/H/C/005102/II/0019, Orphan, ATMP**

Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.8 and 5.1 of the SmPC in order to update the safety and efficacy information based on 24-month follow-up data from all treated patients in cohort 1 of the pivotal clinical study, KTE-C19-102 (ZUMA-2); a Phase 2, multicentre, open-label study evaluating the safety and efficacy of KTE-X19 in subjects with relapsed or refractory (r/r) mantle cell lymphoma (MCL). This submission is in fulfilment of the specific obligation (SOB 004) to confirm the long-term efficacy and safety of

---

---

Tecartus in adult patients with relapsed/refractory (r/r) MCL. In addition, the MAH has taken the opportunity to make minor editorial changes in the SmPC. The RMP version 2.1 has also been submitted.”

---

#### **B.6.14. PRAC assessed ATMP procedures**

#### **B.6.15. Unclassified procedures and worksharing procedures of type I variations**

---

##### **WS2219/G**

**Fluenz Tetra-**

**EMA/H/C/002617/WS2219/0116/G**

**Pandemic influenza vaccine H5N1**

**AstraZeneca-**

**EMA/H/C/003963/WS2219/0050/G**

AstraZeneca AB, Lead Rapporteur: Christophe Focke

---

##### **WS2251/G**

**Eucreas-**

**EMA/H/C/000807/WS2251/0097/G**

**Icandra-**

**EMA/H/C/001050/WS2251/0101/G**

**Zomarist-**

**EMA/H/C/001049/WS2251/0099/G**

Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder

---

##### **WS2260**

**Stayveer-**

**EMA/H/C/002644/WS2260/0036**

**Tracleer-**

**EMA/H/C/000401/WS2260/0101**

Janssen-Cilag International N.V., Lead Rapporteur: Alexandre Moreau

---

##### **WS2262**

**Hexacima-**

**EMA/H/C/002702/WS2262/0130**

**Hexyon-**

**EMA/H/C/002796/WS2262/0134**

Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus

---

##### **WS2272/G**

**Hexacima-**

**EMA/H/C/002702/WS2272/0131/G**

**Hexyon-**

**EMA/H/C/002796/WS2272/0135/G**

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-

---

---

Berghaus

---

**WS2278/G**

**Copalia-**

**EMA/H/C/000774/WS2278/0125/G**

**Copalia HCT-**

**EMA/H/C/001159/WS2278/0100/G**

**Dafiro-**

**EMA/H/C/000776/WS2278/0129/G**

**Dafiro HCT-**

**EMA/H/C/001160/WS2278/0102/G**

**Exforge-**

**EMA/H/C/000716/WS2278/0124/G**

**Exforge HCT-**

**EMA/H/C/001068/WS2278/0099/G**

Novartis Europharm Limited, Lead Rapporteur:

Thalia Marie Estrup Blicher

---

**WS2279/G**

**Ebymect-**

**EMA/H/C/004162/WS2279/0057/G**

**Xigduo-**

**EMA/H/C/002672/WS2279/0067/G**

AstraZeneca AB, Lead Rapporteur: Kristina

Dunder

---

**WS2287/G**

**Filgrastim Hexal-**

**EMA/H/C/000918/WS2287/0064/G**

**Zarzio-**

**EMA/H/C/000917/WS2287/0065/G**

Sandoz GmbH, Lead Rapporteur: Johann

Lodewijk Hillege

---

## **B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY**

### **B.7.1. Yearly Line listing for Type I and II variations**

### **B.7.2. Monthly Line listing for Type I variations**

### **B.7.3. Opinion on Marketing Authorisation transfer (MMD only)**

### **B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)**

### **B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)**

### **B.7.6. Notifications of Type I Variations (MMD only)**

## **C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)**

## **D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)**

## **E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES**

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

### **E.1. PMF Certification Dossiers:**

#### **E.1.1. Annual Update**

#### **E.1.2. Variations:**

#### **E.1.3. Initial PMF Certification:**

### **E.2. Time-Tables – starting & ongoing procedures: For information**

---

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

## F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

## G. ANNEX G

### G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

### G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

#### G.2.1. List of procedures concluding at 16-19 May 2022 CHMP plenary:

---

##### ***Endocrinology-Gynaecology-Fertility-Metabolism***

---

<b>DNL310</b> Treatment of mucopolysaccharidosis type II	The CHMP granted eligibility to PRIME and adopted the critical summary report.
--	--

---

##### ***Uro-nephrology***

---

<b>VX-147</b> Treatment of proteinuric apolipoprotein L1 (APOL1)-mediated chronic kidney disease in patients who have 2 APOL1 genetic mutations (G1/G1, G1/G2, or G2/G2)	The CHMP granted eligibility to PRIME and adopted the critical summary report.
---	--

---

##### ***Cardiovascular Diseases***

---

Treatment of Acute Coronary Syndromes (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
---	---

---

#### G.2.2. List of procedures starting in May 2022 for June 2022 CHMP adoption of outcomes

## H. ANNEX H - Product Shared Mailboxes – e-mail address